



(86) Date de dépôt PCT/PCT Filing Date: 2012/05/08

(87) Date publication PCT/PCT Publication Date: 2012/11/15

(45) Date de délivrance/Issue Date: 2020/12/08

(85) Entrée phase nationale/National Entry: 2013/11/01

(86) N° demande PCT/PCT Application No.: GB 2012/051002

(87) N° publication PCT/PCT Publication No.: 2012/153121

(30) Priorités/Priorities: 2011/05/06 (US61/483,481);  
2011/08/29 (GB1114858.2); 2011/09/06 (US61/531,439)

(51) Cl.Int./Int.Cl. *C07K 16/22* (2006.01),  
*C07K 16/46* (2006.01)


(72) Inventeur/Inventor:  
GEARING, DAVID, AU

(73) Propriétaire/Owner:  
NEXVET AUSTRALIA PTY LTD, AU

(74) Agent: BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.

(54) Titre : ANTICORPS CONTRE LE FACTEUR DE CROISSANCE NEURONALE ET LEURS PROCEDES DE  
PREPARATION ET D'UTILISATION

(54) Title: ANTI-NERVE GROWTH FACTOR ANTIBODIES AND METHODS OF PREPARING AND USING THE SAME



(57) Abrégé/Abstract:

A method of preparing an antibody suitable for use in a canine is provided. Also provided are caninised antibodies which specifically bind to canine neuronal growth factor (NGF) and neutralise the ability of canine NGF to bind to the p75 or TrkA canine NGF receptor. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in a canine using said antibodies and/or nucleic acids.

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



WIPO | PCT



(10) International Publication Number  
**WO 2012/153121 A1**

(43) International Publication Date  
15 November 2012 (15.11.2012)

- (51) International Patent Classification:  
*C07K 16/22* (2006.01) *C07K 16/46* (2006.01)
- (21) International Application Number:  
PCT/GB2012/051002
- (22) International Filing Date:  
8 May 2012 (08.05.2012)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
61/483,481 6 May 2011 (06.05.2011) US  
1114858.2 29 August 2011 (29.08.2011) GB  
61/531,439 6 September 2011 (06.09.2011) US
- (71) Applicant (for all designated States except US): **NVIP PTY LTD** [AU/AU]; 9 Meaden Street, Southbank, Victoria 3006 (AU).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **GEARING, David** [GB/AU]; 9 Meaden Street, Southbank, Victoria 3006 (AU).
- (74) Agent: **MURGITROYD & COMPANY**; Scotland House, 165-169 Scotland Street, Glasgow Strathclyde G5 8PL (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: ANTI-NERVE GROWTH FACTOR ANTIBODIES AND METHODS OF PREPARING AND USING THE SAME




Figure 18

(57) Abstract: A method of preparing an antibody suitable for use in a canine is provided. Also provided are caninised antibodies which specifically bind to canine neuronal growth factor (NGF) and neutralise the ability of canine NGF to bind to the p75 or TrkA canine NGF receptor. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in a canine using said antibodies and/or nucleic acids.

# WO 2012/153121 A1

---

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

## ANTI-NERVE GROWTH FACTOR ANTIBODIES AND METHODS OF PREPARING AND USING THE SAME

### Field of the Invention

5 The present invention relates to antibodies, and fragments thereof, which act as antagonists of canine nerve growth factor. The invention extends to methods of preparing same and to the therapeutic use of these antibodies and fragments in treating conditions associated with nerve growth factor such as pain, pain related disorders and conditions which result in the occurrence of chronic pain in canines.

### Background to the Invention

10 Nerve growth factor (NGF) is a naturally occurring secreted protein which consists of an alpha, beta and gamma polypeptide chain. NGF is a member of the neurotrophin family and is implicated in a number of different roles. NGF promotes survival and differentiation of sensory and sympathetic neurons and signals via two membrane bound receptors, p75, a low affinity NGF receptor and TrkA, a transmembrane tyrosine kinase and a high affinity NGF receptor. The binding of NGF to TrkA or p75 results in an upregulation of neuropeptides in sensory neurons.

20 The use of NGF antagonists to treat pain and pain sensitivity in humans has been described (Cattaneo A., Curr. Op. Mol. Ther. 2010 12(1):94-106). For example, International Patent Application No. WO 2006/131951 describes a humanised form of the rat alphaD11 ( $\alpha$ D11, aD11) monoclonal antibody. The  $\alpha$ D11 antibody has binding specificity to mouse NGF, but is also known to bind to human and rat forms of NGF. Humanisation of the  $\alpha$ D11 rat derived monoclonal antibody is required prior to administration to humans in order to minimise the production of neutralising antibodies which result from a human anti-mouse antibody (HAMA) response being mounted against rodent derived antibodies. Furthermore, the replacement of mouse constant domains with human constant domains allows downstream effector functions to be selected for.

Pain management in canines is currently provided through administration of analgesic drugs of several classes, including local and general anaesthetics, opioid analgesics,  $\alpha 2$  agonists, non-steroidal anti-inflammatory drugs (NSAIDs) and steroids. Each of these needs to be administered frequently and also has limitations in efficacy and safety. There is accordingly a need for an infrequently dosed, long lasting and efficacious form of pain relief for canines suffering from chronic pain, such as those with cancer pain or arthritis.

While NGF is expressed in canine tissues and the canine NGF molecule has been characterised (Eisele I. Wood IS. German AJ. Hunter L. Trayhurn P." Adipokine gene expression in dog adipose tissues and dog white adipocytes differentiated in primary culture" Hormone & Metabolic Research. 37(8):474-81, 2005 Genbank XP\_540250), no antagonist to canine NGF has been described, nor has the use of blocking NGF mediated signalling in canines to prevent or alleviate pain. The use in canines of known antibodies which act as anti-NGF antagonists in other species would not be feasible due to the production of neutralising antibodies.

Furthermore, the production of a chimeric antibody comprising canine derived constant domains and variable domains derived from a known anti-NGF antibody such as alphaD11 could not be guaranteed to bind to canine NGF. Furthermore, such an antibody may exhibit cross-reactivity to other target epitopes which may be present in canines, but not present in the species from which the antibody was originally derived. Furthermore, the production of neutralising antibodies would limit the long term therapeutic administration of the antibody, this being a particularly important requirement when treating a chronic pain related condition or a cancerous condition. Likewise, the production of a caninised form of an anti-NGF antibody using CDR grafting, or a related technique may also result in neutralising antibody production and may further exhibit a reduction in antigen binding affinity and avidity. Accordingly, there is a serious need for binding members which act as antagonists of canine NGF for use in pain management in canines, wherein the binding members retain high levels of binding affinity and avidity, while avoiding the production of neutralising antibodies there against.

Summary of the invention

Following extensive efforts, the present inventor has surprisingly identified a method for preparing antibodies which produces non-immunogenic antibodies and binding fragments which bind specifically to canine NGF and which neutralise canine NGF biological activity. In particular, it is demonstrated herein, quite unexpectedly, that the binding of the antibodies and binding fragments of the invention to canine NGF sequesters the biological activity of canine NGF by inhibiting the binding of canine NGF to the high affinity TrkA receptor or to the p75 receptor. This, in turn, prevents the upregulation of neuropeptides in sensory neurons with the resulting effect that the sensation of pain will be reduced or removed. The antibodies have been produced using recombinant DNA methods and are unexpectedly non-immunogenic, that is, neutralising antibodies are not raised against them following administration to a canine subject. Such a finding is entirely surprising and unexpected, as the antibodies were not produced using standard methodologies, such as CDR grafting, or the like.

According to a first aspect of the invention there is provided a method of preparing an antibody suitable for use in a canine comprising or consisting essentially of the steps of:

- providing a donor antibody from a species other than a canine, wherein the donor antibody has binding specificity for a target antigen present in canines;
- comparing each amino acid residue of the amino acid sequence of framework regions of the donor antibody with each amino acid residue present at a corresponding position in the amino acid sequence of framework regions of one or more canine antibodies to identify one or more amino acid residues within the amino acid sequence of the framework regions of the donor antibody that differ from one or more amino acid residues at the corresponding position within the amino acid sequence of framework regions of the one or more canine antibodies; and
- substituting the one or more identified amino acid residues in the donor antibody with the one or more amino acid residues present at the corresponding position in the one or more canine antibodies.

The method of the present invention modifies a donor antibody for use in a canine in such a way that the modified antibody does not contain any amino acid in any position within the framework regions which would be foreign at that position in canines. The modified antibody therefore retains the specificity and affinity of the donor antibody for the target antigen, but importantly is modified such that no potentially foreign epitopes are created. The modified antibody is therefore not seen as foreign in canines and hence does not induce an immune response in canines which could lead to a neutralisation of the efficacy of the antibody, especially following long term administration.

In certain embodiments, the step of substituting the one or more identified amino acid residues comprises substituting the one or more identified amino acid residues with the one or more amino acid residues present at the corresponding position which have the highest homology to the one or more substituted amino acid residues.

In certain embodiments, the method further comprises the step of replacing constant domains of the heavy chain and/or light chain of the donor antibody with constant domains of a heavy and/or light chain derived from a canine antibody.

Typically, the constant domain of the heavy chain is replaced with a type HCA or HCD canine constant domain.

In certain embodiments, the target antigen is nerve growth factor (NGF).

The method of the first aspect of the invention does not comprise CDR grafting. Antibodies prepared according to the method of the first aspect of the invention comprise CDRs of the donor antibody, caninised framework regions prepared according to the method of the first aspect of the invention and canine constant domains.

The present invention extends to antibodies prepared according to the first aspect of the present invention such as those described below.

Accordingly, according to a further aspect of the invention there is provided a caninised antibody or binding fragment thereof which binds specifically to canine neuronal growth factor (NGF). Typically, the caninised antibody or binding  
5 fragment thereof neutralises NGF biological function, when bound thereto. That is, the binding of the caninised antibody or binding fragment to NGF sequesters the ability of NGF to bind to the TrkA receptor or to the p75 receptor. In certain embodiments, the caninised antibody, or binding fragment thereof, binds to NGF with a binding affinity  $K_D$  of  $1 \times 10^{-8}$  or less.

10 In a further or related aspect of the invention there is provided a neutralising antibody, or an antigen binding fragment thereof, which is capable of specifically binding to canine nerve growth factor (NGF), the antibody or antibody binding fragment comprising, consisting of or consisting essentially of a light chain variable  
15 region comprising the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:3 or an amino acid sequence which has an identity of at least 85, 90, 95 or 99% thereto. In certain embodiments said identity is over a length of at least about 15 amino acids, preferably about 20 amino acids, more preferably about 25 amino acids.

20 In some embodiments the neutralising antibody is a monoclonal antibody. In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a caninised antibody, that is, an antibody which has an amino acid sequence which has been de-immunised such that neutralising antibodies will not  
25 be produced there against when administered to a canine subject. In certain embodiments, the caninised antibody is prepared according to the method of preparing an antibody of the first aspect of the invention. Typically the heavy chain constant domains of the antibody are selected or modified by way of amino acid substitution or deletion such that the constant domains do not mediate  
30 downstream effector functions.



In some embodiments, the antibody or antibody binding fragment comprises, consists of, or consists essentially of a light chain comprising the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:10, or an amino acid sequence which has at least 85, 90, 95 or 99% sequence homology thereto. In certain  
5       embodiments said identity is over a length of at least about 15 amino acids, preferably about 20 amino acids, more preferably about 25 amino acids.

In a further or related aspect, there is provided a neutralising antibody, or an antigen binding fragment thereof, which is capable of specifically binding to canine  
10       nerve growth factor (NGF), the antibody or antibody binding fragment comprising, consisting of or consisting essentially of a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or an amino acid sequence which has an identity of at least 85, 90, 95 or 99% thereto. In certain  
15       embodiments said identity is over a length of at least about 15 amino acids, preferably about 20 amino acids, more preferably about 25 amino acids.

Typically, the variable region of the heavy chain (VH) is conjoined to a further amino acid sequence which comprises at least one immunoglobulin constant domain. In certain embodiments, the immunoglobulin constant domain is derived  
20       from an antibody of the subclass IgG (immunoglobulin G) to form the complete heavy chain of the caninised antibody of the invention. Four different canine constant domains are known. Typically, said constant domains comprise CH1, CH2 and CH3 along with a suitable linker (or "hinge") located between the CH1 and CH2 domains. Typically, the anti-canine NGF antibody of the invention  
25       comprises a heavy chain variable domain conjoined to a constant domain, wherein the constant domain does not mediate downstream effector functions such as complement fixation, ADCC, Fc receptor binding, or the like. Typically said heavy chain has a canine heavy chain isotype A or D.

30       In certain embodiments, the antibody or antibody binding fragment comprises, consists of, or consists essentially of a heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:7, SEQ

ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14, or an amino acid sequence which has a sequence identity of at least 85, 90, 95 or 99% thereto. In certain embodiments said identity is over a length of at least about 15 amino acids, preferably about 20 amino acids, more preferably about 25 amino acids.

In certain further embodiments, the antibody or binding fragment may comprise a heavy chain where at least one amino acid residue in the constant domain has been substituted or deleted in order to prevent the glycosylation of that amino acid residue. Accordingly, in certain further embodiments, the antibody or antibody binding fragment comprises, consists of, or consists essentially of a heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21 and SEQ ID NO:22, or an amino acid sequence which has a sequence identity of at least 85, 90, 95 or 99% thereto. In certain embodiments said identity is over a length of at least about 15 amino acids, preferably about 20 amino acids, more preferably about 25 amino acids.

In some embodiments, antibodies or fragments having a heavy chain constant domain which do not mediate downstream effector functions such as complement fixation, ADCC, Fc receptor binding, or the like are preferred. Such heavy chains may comprise heavy chains of the canine derived subtype IgG-A and may have an amino acid sequence of SEQ ID NO:6, 11, 15 or 19. Further, such heavy chains may comprise heavy chains of the canine derived subtype IgG-D and may have an amino acid sequence of SEQ ID NO:9, 14, 18 and 22.

In a further or related aspect, the present invention extends to a neutralising antibody, or an antigen binding fragment thereof, which is capable of specifically binding to canine nerve growth factor (NGF), the antibody or antibody binding fragment comprising, consisting of or consisting essentially of a light chain and a heavy chain wherein the variable region of the light chain (VL) comprises an amino acid sequence of SEQ ID NO:1 or SEQ ID NO:3 or an amino acid sequence which

has a sequence identity of at least 85, 90, 95 or 99% thereto, and wherein the variable region of the heavy chain (VH) comprises, consists or consists essentially of an amino acid sequence which is identical or substantially homologous to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or an amino acid sequence which has a sequence identity of at least 85, 90, 95 or 98% thereto. In certain embodiments said identity is over a length of at least about 15 amino acids, preferably about 20 amino acids, more preferably about 25 amino acids.

In certain embodiments, the antibody or binding member comprises a light chain which comprises, consists of or consists essentially of the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:10, or to a sequence having an amino acid identity of at least 85%, more preferably of 95% and most preferably at least 98% identity thereto. In certain embodiments said identity is over a length of at least about 15 amino acids, preferably about 20 amino acids, more preferably about 25 amino acids.

In certain embodiments, the antibody or binding member comprises a heavy chain which comprises, consists of or consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14, or an amino acid sequence having a sequence identity of at least 85%, more preferably of 95% and most preferably at least 98% thereto. In certain embodiments said identity is over a length of at least about 15 amino acids, preferably about 20 amino acids, more preferably about 25 amino acids.

In certain embodiments, the antibody may be conjugated to at least one reporter molecule.

In certain further embodiments at least one residue in the constant domain can be substituted or deleted in order to prevent the glycosylation of that residue. Accordingly, in certain further embodiments, the antibody or antibody binding fragment comprises, consists of, or consists essentially of a heavy chain

comprising the amino acid sequence selected from the group consisting of SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21 and SEQ ID NO:22, or a sequence having an amino acid identity of at least 85%, more preferably of 95% and most preferably at least 98% identity thereto. In certain embodiments said identity is over a length of at least about 15 amino acids, preferably about 20 amino acids, more preferably about 25 amino acids.

The inventor has further defined a series of framework regions (FR) which can be combined with complementarity determining regions (CDRs) to form caninised heavy and light chain variable domains. Each of the heavy and light chain domains has 4 framework regions, designated FR1, FR2, FR3 and FR4.

An antibody molecule may comprise a heavy chain variable domain comprising CDR1, CDR2 and CDR3 regions and associated interposed framework regions. The heavy chain variable domain (VH) CDRs are known as HCDRs, with these CDRs being found at the following positions according to the Kabat numbering system: VHCDR1 – Kabat residues 31-35, VHCDR2 – Kabat residues 50-65, VHCDR3 – Kabat residues 95-102 (Kabat EA et al. (1991) Sequences of proteins of immunological interest, 5<sup>th</sup> edition. Bethesda: US Department of Health and Human Services).

Furthermore, an antibody further comprises a light chain variable domain comprising CDR1, CDR2 and CDR3 regions and associated interposed framework regions. The light chain variable domain (VL) CDRs are known as VLCDRs, with these CDRs being found at the following amino acid residue positions according to the Kabat numbering system: VLCDR1 – Kabat residues 24-34, VLCDR2 – Kabat residues 50-56, VLCDR3 – Kabat residues 89-97.

A light or heavy chain variable domain comprises four framework regions, FR1, FR2, FR3 and FR4, interposed with CDRs in the following arrangement: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.

In a yet further aspect, the present invention extends to an anti-NGF antibody, or an NGF binding fragment thereof, the antibody or antibody binding fragment comprising a light chain variable region comprising at least one of:

- 5           an FR1 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:23 or SEQ ID NO:24,
- an FR2 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:25,
- an FR3 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:26 or SEQ ID NO:27,
- 10          an FR4 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:28,

and/or a heavy chain variable region comprising at least one of:

- an FR1 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:29,
- 15          an FR2 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:30,
- an FR3 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:31 or SEQ ID NO:32,
- 20          an FR4 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:33.

Typically the light and heavy chain CDRs are derived from an antibody which has binding specificity to canine NGF.

25

Typically, the production of the caninised anti-canine NGF antibody of the invention does not require back mutations to be introduced into the framework regions of the light or heavy chain variable domains.

30

In certain embodiments, the light chain variable domain comprising said at least one framework region described above is conjoined to a canine derived light chain constant domain, typically a light chain kappa constant domain, but optionally a

lambda light chain. In certain embodiments, said light chain comprises an FR1 region with an amino acid sequence of SEQ ID NO:23 or SEQ ID NO:24, an FR2 region with an amino acid sequence of SEQ ID NO:25, an FR3 region with an amino acid sequence of SEQ ID NO:26 or SEQ ID NO:27, and an FR4 region with an amino acid sequence of SEQ ID NO:28 or a framework region with an amino acid sequence which has a sequence identity of at least 85, 90, 95 or 98% to the foregoing. In certain embodiments said identity is over a length of at least about 5 amino acids, preferably about 10 amino acids.

In certain further embodiments, the heavy chain variable region comprising at least one of the framework regions described above is conjoined to a canine derived heavy chain constant domain. In certain embodiments, the amino acid sequence of the constant domain lacks any post-translational modifications, or may be modified to remove any or all residues which may be subject to N-linked or O-linked glycosylation, such that the constant domains are aglycosylated. In certain embodiments the heavy chain comprises an FR1 region with an amino acid sequence of SEQ ID NO:29, an FR2 region with an amino acid sequence of SEQ ID NO:30, an FR3 region with an amino acid sequence of SEQ ID NO:31 or SEQ ID NO:32 and an FR4 region with an amino acid sequence of SEQ ID NO:33 or a framework region with an amino acid sequence which has a sequence identity of at least 85, 90, 95 or 98% to the foregoing. In certain embodiments said identity is over a length of at least about 5 amino acids, preferably about 10 amino acids.

In certain further embodiments, modifications may be made to the framework regions described herein. That is, the inventor has identified that for some residues in each framework region, there is a choice of amino acid residues which may be present at a given position. Importantly, these framework region modifications do not result in a conformational change to the complementarity determining regions, as this may alter the binding specificity and/or affinity of the resulting antibody. In certain embodiments, the invention extends to introducing 2 or more amino acid substitutions to the amino acid residues of the framework regions of the light chain variable region and/or heavy chain variable region.

Accordingly, in certain further embodiments, the invention extends to polypeptides, such as an antibody, or antigen binding fragment thereof, which comprises a light chain variable domain having an FR1 region comprising the amino acid sequence of SEQ ID NO:23 which has been modified by one or more of the following amino acid substitutions (where the amino acids are denoted by their single letter code): amino acid residue Q at position 3 (Q3) is replaced by the amino acid residue V, T5 is M, S7 is T, A9 is L, L13 is V, Q15 is P or R, E16 is G, K18 is T or P, V19 is A, T20 is S, and T22 is S. Furthermore, one or more of the following substitutions may be further be provided: T5 is I, A9 is P, S12 is A, S14 is R or T, E16 is D, E17 is D, K18 is A, E or L, T22 is Y and C23 is Y.

In certain further embodiments, where the light chain variable domain has the FR1 region comprising the amino acid sequence of SEQ ID NO:24, this may be modified by one or more of the following amino acid substitutions: amino acid residue V at position 3 (V3) is replaced by the amino acid residue Q, T5 is M, S7 is T, A9 is L, L13 is V, Q15 is P or R, E16 is G, K18 is T or P, V19 is A, T20 is S, and T22 is S. Furthermore, one or more of the following substitutions may be further be provided: T5 is I, A9 is P, S12 is A, S14 is R or T, E16 is D, E17 is D, K18 is A, E or L, T22 is Y and C23 is Y.

In certain further embodiments, the light chain FR2 region having the amino acid sequence of SEQ ID NO:25 may be modified by one or more of the following amino acid substitutions: Y2 is F, Q3 is R, A9 is S, K11 is Q, and L12 is R.

Furthermore, Y2 can be I or L, Q3 can be I or L, Q4 can be H, K5 can be R, P6 can be A or S, G7 can be D, A9 can be P or T, K11 can be E or R, L12 can be A, G, P or S, I14 can be L, and Y15 can be E, F, N, S or V.

In certain further embodiments, the light chain FR3 region having the amino acid sequence of SEQ ID NO:26 may be modified by one or more of the following amino acid substitutions: S4 is D, E14 is D, Y15 is F, S16 is T, L17 is F, T18 is K, N20 is S, L22 is V, S24 is P, V27 is A, F31 is Y. Furthermore, G1 can be A, V2

can be A, P3 can be S, F6 can be L or V, S7 can be I, G8 can be A, T13 can be A, S16 can be R, T18 can be R, S24 can be A, E25 can be D, G, I or N, V27 can be G, S or T, A28 can be G, and V29 can be I or L.

5 In certain further embodiments, where the light chain variable domain has the FR3 region comprising the amino acid sequence of SEQ ID NO:27, this may be modified by one or more of the following amino acid substitutions: S4 is D, E14 is D, F15 is Y, S16 is T, L17 is F, T18 is K, S20 is N, L22 is V, P24 is S, V27 is A, Y31 is F. Furthermore, G1 can be A, V2 can be A, P3 can be S, F6 can be L or V,  
10 S7 can be I, G8 can be A, T13 can be A, S16 can be R, T18 can be R, S24 can be A, E25 can be D, G, I or N, V27 can be G, S or T, A28 can be G, and V29 can be I or L.

In certain further embodiments, the light chain FR4 region having the amino acid  
15 sequence of SEQ ID NO:28 may be modified by one or more of the following amino acid substitutions: E8 is D. Furthermore, G2 can be S, A3 can be P, Q or T, G4 can be E, T5 can be P, K6 can be Q or S, V7 can be L or W, E8 can be R, or L9 can be I.

20 In certain further embodiments, the heavy chain FR1 region having the amino acid sequence of SEQ ID NO:29 may be modified by one or more of the following amino acid substitutions: D10 is G, N13 is Q, G15 is T, G16 is E, T17 is S, T19 is R, V24 is A, S28 is T, L29 is F, T30 is S. Furthermore, E1 can be D or G, V2 can be E, G, I, L or M, Q3 can be A, E, H, K, L, P, R, S or V, L4 can be P or V, V5 can  
25 be A, E, L or M, E6 can be A or Q, S7 can be F, L or T, G9 can be E, D10 can be A, E, N or T, L11 can be Q, R, V or W, V12 can be A, I or M, N13 can be K or R, P14 can be F or T, G15 can be A or E, G16 can be A, T17 can be P, L18 can be R, T19 can be G, K or V, L20 can be I or V, S21 can be Y, V23 can be A, E, I or L, V24 can be G, I, S or T, S25 can be G, P or T, G26 can be D, R or T, F27 can be  
30 D, I, L, S, T or V, S28 can be A, D, I, L, M, N, P or R, L29 can be I, M or V, T30 can be D, G, H, I, K, N, R, V.



In certain further embodiments, the heavy chain FR2 region having the amino acid sequence of SEQ ID NO:30 may be modified by one or more of the following amino acid substitutions: L6 is P, R8 is K, E11 is Q, G14 is A. Furthermore, W1 can be C, V2 can be A, F, I or L, Q4 can be H or L, A5 can be D, G, P, S, T or V, G7 can be E, L or R, R8 can be A, E, G, M or Q, G9 can be D, E, R, T or V, L10 can be F, M or P, E11 can be D, H, L, P or R, W12 can be C, F, L, M, S or Y, V13 can be F, I or L, G14 can be L, S or T.

In certain further embodiments, the heavy chain FR3 region having the amino acid sequence of SEQ ID NO:31 may be modified by one or more of the following amino acid substitutions: L2 is F, T5 is S, T8 is N, S9 is A, S11 is N, V13 is L, F14 is Y, K16 is Q, H18 is N, Q21 is R, S22 is A, T27 is V, R32 is K. Furthermore, R1 can be Q, L2 can be V, T3 can be A, I or S, I4 can be L, M, T or V, T5 can be A or F, R6 can be K, D7 can be E or N, T8 can be D, G, I or S, S9 can be D, G, P, T or V, K10 can be E, G, M, N, Q or R, S11 can be D, H, K or R, T12 can be A, I, M or S, V13 can be A, I or M, F14 can be H, S or T, L15 can be I, K16 can be A, D, E, H or R, M17 can be L, H18 can be D, K, P, R, S or T, S19 can be D, G, N, R or T, L20 can be V, Q21 can be G, I, K, S or T, S22 can be D, G, P, T or V, E23 can be A, D or V, T25 can be A, M or S, A26 can be G or V, T27 can be F, I, K, L, M or Q, Y28 can be H, Y29 can be F or H, A31 can be C, G, L, M, R, S, T or V, R32 is A, D, E, G, I, L, M, N, P, Q, S, T or V.

In certain further embodiments, where the heavy chain variable domain has the FR3 region comprising the amino acid sequence of SEQ ID NO:32, this may be modified by one or more of the following amino acid substitutions: L2 is F, T5 is S, T8 is N, S9 is A, S11 is N, V13 is L, F14 is Y, Q16 is K, H18 is N, R21 is Q, S22 is A, T27 is V, R32 is K. Furthermore, R1 can be Q, L2 can be V, T3 can be A, I or S, I4 can be L, M, T or V, T5 can be A or F, R6 can be K, D7 can be E or N, T8 can be D, G, I or S, S9 can be D, G, P, T or V, K10 can be E, G, M, N, Q or R, S11 can be D, H, K or R, T12 can be A, I, M or S, V13 can be A, I or M, F14 can be H, S or T, L15 can be I, K16 can be A, D, E, H or R, M17 can be L, H18 can be D, K, P, R, S or T, S19 can be D, G, N, R or T, L20 can be V, Q21 can be G, I, K, S or

T, S22 can be D, G, P, T or V, E23 can be A, D or V, T25 can be A, M or S, A26 can be G or V, T27 can be F, I, K, L, M or Q, Y28 can be H, Y29 can be F or H, A31 can be C, G, L, M, R, S, T or V, R32 is A, D, E, G, I, L, M, N, P, Q, S, T or V.

5 In certain further embodiments, the heavy chain FR4 region having the amino acid sequence of SEQ ID NO:33 may be modified by one or more of the following amino acid substitutions: L6 is S. Furthermore, W1 can be L, G2 can be A or S, Q3 can be D, H, P or R, T5 can be A, I, N or S, L6 can be P, Q or R, V7 can be I, L or P, T8 can be A, F, I, L, P, S or Y, V9 can be A, S10 can be A, C, P or T, S11  
10 can be A, L or P.

In certain embodiments of the above aspects of the invention, the antibody is a monoclonal antibody. Typically the antibody is a caninised antibody.

15 In certain embodiments of the above aspects of the invention, the caninised NGF neutralising antibody of the invention, or the binding fragment derived therefrom specifically binds to canine NGF (nerve growth factor) with a binding affinity having an equilibrium dissociation constant ( $K_D$ ) of  $1 \times 10^{-8}$  or less. Furthermore, it is preferred that the caninised antibodies are not cross-reactive to any other epitopes  
20 present in canines, and further that neutralising antibodies are not generated against the antibodies of the invention when they are administered to a canine. Furthermore, it is preferred that the constant domains of the antibodies do not mediate any downstream effector functions including, but not limited to, complement fixation and activation, ADCC and Fc receptor binding and activation.

25 In certain embodiments of the above aspects of the invention, the antibody, or antigen binding fragment thereof, has a serum half-life in canines of at least one week. Typically, the serum half-life is at least 8 days. Typically, the antibody is not immunogenic in canines.

30 In certain embodiments of the above aspects of the invention, the antibody, or antigen binding fragment thereof, is purifiable or purified by a method comprising

anion exchange chromatography, hydrophobic interaction chromatography and size exclusion chromatography. In alternative embodiments, the antibody, or antigen binding fragment thereof, is purifiable or purified by a method comprising Captopadhere affinity chromatography followed by anion exchange  
5 chromatography.

In certain embodiments, the antibody, or antigen binding fragment thereof, does not mediate downstream effector functions. Typically the antibody or binding fragment has a canine heavy chain isotype A or D.

10 In certain embodiments, the caninised antibody is prepared according to the method of preparing an antibody of the first aspect of the invention.

In certain further embodiments, modifications to the amino acid sequence of the constant regions of the heavy chain may be made to the antibodies of the

15 invention. Said modification may involve the addition, substitution or deletion of one or more amino acid residues. Said amino acid changes are typically performed in order to modify the functional characteristics of the antibody. For example, amino acid modification may be performed to prevent downstream effector functions mediated by the antibody constant domains, for example by  
20 preventing the ability of the antibody to bind to Fc receptors, activate complement or induce ADCC. Furthermore, modifications may be made to the amino acid residues of the hinge region of the heavy chain constant domain in order to modify the circulatory half life of an antibody when it is administered to a canine.

25 The present invention extends to antibody fragments which bind to canine NGF and sequester its ability to bind to the p75 or TrkA receptors.

In certain embodiments the antibody binding fragment may comprise a heavy chain and light chain sequence of the invention being connected by a flexible  
30 linker to form a single chain antibody.

A single chain Fv (scFv) comprises a VH and VL domain. The VH and VL domains associate to form a target binding site. These 2 domains are covalently linked by a peptide linker. A scFv molecule can have the form of VL-linker-VH, in cases where the light chain variable domain is required at the N-terminal, or as  
5 VH-linker-VL in cases where the VH domain is required at the N-terminal.

Accordingly, in certain further embodiments, the antigen binding fragment is a single chain Fv (scFv) antibody fragment. In certain further embodiments, the antibody binding fragment is selected from the group consisting of, but not limited to, a Fab antibody fragment, a Fab' antibody fragment, a F(ab')<sub>2</sub> antibody  
10 fragment, an Fv antibody fragment, a scFV antibody fragment, and the like.

In some embodiments, the invention provides multispecific or multivalent antibodies comprising an anti-NGF antibody or binding fragment of the invention coupled or conjoined to other antibodies with different binding specificities for use  
15 in combination therapy. A multispecific antibody comprises at least one antibody or binding fragment specific to a first NGF epitope, and at least one binding site specific to another epitope present on NGF, or to a different antigen. A multivalent antibody comprises antibodies or antibody binding fragments which have binding specificity to the same NGF epitope. Accordingly, in certain embodiments, the  
20 invention extends to an antibody fusion protein comprising four or more Fv regions or Fab regions of the caninised antibodies of the present invention. A yet further embodiment extends to an antibody fusion protein comprising one or more Fab region derived from an antibody described herein along with one or more Fab or Fv regions from antibodies specific for NGF. In certain further embodiments, the  
25 invention extends to a bispecific antibody, wherein an antibody or binding fragment thereof according to the present invention is linked to a secondary antibody or binding fragment thereof which has binding specific for a secondary target, said target not being NGF. Preferably said secondary target assists in preventing NGF mediated signalling through the p75 or TrkA receptors. Such multivalent,  
30 bispecific or multispecific antibodies can be made by a variety of recombinant methods which would be well known to the person skilled in the art.

A yet further aspect of the invention provides an anti-neurotrophin neutralising antibody comprising a light chain variable domain having the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:3 and/or a heavy chain variable domain having the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4. In certain embodiments, the neurotrophin is canine nerve growth factor (NGF).

A yet further aspect of the invention provides a method for treating, inhibiting or ameliorating pain in a canine, the method comprising the steps of:

- providing a therapeutically effective amount of an anti-canine NGF antibody, or antigen binding fragment thereof, and
- administering the same to a canine in need thereof.

In certain embodiments, the antibody is a caninised antibody.

In certain embodiments, the antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:3 or a sequence which has at least 85% identity thereto and/or a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or an amino acid sequence having at least 85% sequence homology thereto.

In certain embodiments, the antibody comprises a light chain having the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:10 or a sequence having a sequence identity of at least 85% thereto and/or a heavy chain which comprises, consists of or consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14, or a sequence having an amino acid identity of at least 85% and more preferably at least 98% identity thereto.

In certain embodiments, the anti-canine NGF antibody or antigen binding fragment thereof is any of those provided by the foregoing aspects of the invention.

In certain embodiments, the pain is neuropathic pain. In particular, the pain may be peri-operative, post-operative or post-surgical pain. Post-operative pain may result following any operating procedure which in canines may include, but is not limited to, orthopaedic surgery, soft tissue surgery, ovariohysterectomy  
5 procedures, castration procedures and the like. In certain further embodiments, the pain is chronic pain associated with cancer or a cancerous condition (oncologic pain). In certain further embodiments, the pain is associated with, or resulting from, rheumatoid arthritis or osteoarthritis. In certain embodiments, the pain is inflammatory pain or pruritic pain.

10 According to a yet further aspect of the present invention there is provided a method for the treatment of arthritis or an arthritic condition in a canine subject, said method comprising the steps of:

- providing a therapeutically effective amount of an anti-canine NGF  
15 antibody according to the invention or antigen binding fragment thereof, and
- administering the same to a canine in need thereof.

In certain embodiments, the antibody is a caninised antibody. In certain  
20 embodiments, the antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:3 or a sequence which has at least 85% identity thereto and/or a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or an amino acid sequence having at least 85% sequence homology thereto.

25 In certain embodiments, arthritis or arthritic condition includes the conditions selected from the group consisting of immune mediated polyarthritis, rheumatoid arthritis, osteoarthritis and related conditions.

Typically, the treatment of the arthritis or arthritic condition comprises ameliorating,  
30 inhibiting, reducing, suppressing or delaying the onset of pain associated with, or attributable to, the arthritic condition.

A further aspect of the present invention provides a method for the treatment of a condition caused by, associated with or resulting in increased expression of canine NGF or increased sensitivity to NGF in a canine subject, said method comprising the steps of:

- 5           - providing a therapeutically effective amount of a caninised anti-canine NGF antibody according to the invention or antigen binding fragment thereof, and
- administering the same to a canine in need thereof.

10       According to a yet further aspect of the present invention there is provided a method for the treatment of a tumour induced to proliferate by NGF in a canine and conditions associated therewith, said method comprising the steps of:

- providing a therapeutically effective amount of an anti-canine NGF antibody according to the invention or antigen binding fragment thereof, and
- 15       - administering the same to a canine in need thereof.

In certain embodiments, the tumour is an osteosarcoma. In certain embodiments, the tumour is induced to proliferate by autocrine or paracrine NGF.

20       In certain embodiments, the foregoing methods of the invention further comprise the step of co-administering at least one further agent which may enhance and/or complement the effectiveness of the anti-NGF antibody of the invention. For example, the antibody or antigen binding fragment thereof may be co-administered along with at least one analgesic, NSAID, opioid, corticosteroid or steroid.

25       Examples of suitable analgesics include, but are not limited to, butorphanol, buprenorphine, fentanyl, flunixin meglumine, merpidine, morphine, nalbuphine and derivatives thereof. Suitable NSAIDS include, but are not limited to, acetaminophen, acetylsalicylic acid, carprofen, etodolac, ketoprofen, meloxicam,

30       firocoxib, robenacoxib, deracoxib and the like.

In certain further embodiments, the at least one further agent may be a therapeutically active agent which may be one or more of the group selected from an antibiotic, an antifungal therapeutic agent, an antiprotozoal therapeutic agent, an antiviral therapeutic agent or similar therapeutic agents. Furthermore the at least one further agent may be an inhibitor of mediator(s) of inflammation such as a PGE-receptor antagonist, an immunosuppressive agent, such as cyclosporine, or an anti-inflammatory glucocorticoids. In certain further embodiments the at least one further agent may be an agent which is used for the treatment of cognitive dysfunction or impairment, such as memory loss or related conditions which may become increasingly prevalent in older canines. Further still, the at least one further agent may be an anti-hypertensive or other compound used for the treatment of cardiovascular dysfunction, for example, to treat hypertension, myocardial ischemia, congestive heart failure and the like. Further still, the at least one further agent may be a diuretic, vasodilator, beta-adrenergic receptor antagonist, angiotensin-II converting enzyme inhibitor, calcium channel blocker or HMG-CoA reductase inhibitor.

In certain embodiments, the antibody or antigen binding fragment is administered to the canine as part of the foregoing methods at a dose ranging from about 0.01 mg/kg of body weight to about 10 mg/kg of body weight, in particular from 0.03 mg/kg of body weight to about 3 mg/kg of body weight.

In various further aspects, the present invention extends to a composition comprising an antibody or binding fragment thereof according to any foregoing aspect of the invention. In certain embodiments, the composition further comprises at least one pharmaceutically acceptable carrier.

A yet further aspect of the invention provides a pharmaceutical composition for treating pain or a condition resulting in or caused by chronic pain in a canine or a tumour induced to proliferate by NGF, comprising a pharmaceutically effective amount of an antibody according to the present invention, along with at least one pharmaceutically acceptable carrier, excipient or diluent.



In certain embodiments, the composition may further comprise at least one analgesic, NSAID, opioid, corticosteroid or steroid.

- 5 In various further aspects, the present invention extends to an isolated nucleic acid which encodes the antibody or antibody binding fragments of the invention.

Accordingly, a yet further aspect of the invention provides an isolated nucleic acid that encodes an antibody or antigen binding fragment according to any of the  
10 foregoing aspects of the invention.

In certain embodiments, the polynucleotide encodes a light chain variable domain of an anti-canine NGF antibody or antibody fragment having the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:3, or a light chain having the amino acid  
15 sequence of SEQ ID NO:5 or 10.

In certain further embodiments the polynucleotide encodes a heavy chain variable domain of an anti-canine NGF antibody or antibody fragment having the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or a heavy chain having the  
20 amino acid sequence selected from the group consisting of SEQ ID NO:6- SEQ ID NO:9, SEQ ID NO:11- SEQ ID NO:14, SEQ ID NO:15- SEQ ID NO:18 and SEQ ID NO:19- SEQ ID NO:22.

In certain embodiments, the isolated nucleic acid further encodes one or more  
25 regulatory sequences operably linked thereto.

In a further aspect there is provided an expression vector comprising a polynucleotide comprising a polynucleotide encoding a heavy and/or light chain variable domain or a heavy and/or light chain constant domain of the invention. In  
30 certain embodiments the expression vector further comprises one or more regulatory sequences. In certain embodiments the vector is a plasmid or a retroviral vector.

A yet further aspect provides a host cell incorporating the expression vector of the foregoing aspect of the invention. A further aspect of the invention provides a host cell which produces the antibody of any of the foregoing aspects of the invention.

5

A yet further aspect of the invention provides a method for producing an anti-canine NGF neutralising antibody, the method comprising the step of culturing the host cell of the foregoing aspect of the invention to allow the cell to express the anti-canine NGF neutralising antibody.

10

A further aspect of the present invention provides a method of purifying an anti-canine NGF antibody according to the invention comprising the steps of:

- (i) anion exchange chromatography;
- (ii) hydrophobic interaction chromatography; and
- 15 - (iii) size exclusion chromatography.

A further aspect of the present invention provides a method of purifying an anti-canine NGF antibody according to the invention comprising the steps of:

- (i) Captoadhere affinity chromatography; and
- 20 - (ii) anion exchange chromatography.

A yet further aspect of the present invention provides a method of producing an anti-canine NGF caninised antibody according to the invention comprising the steps of expressing one or more of the polynucleotides / nucleic acids or vectors of the foregoing aspects of the invention which express the light and/or heavy chains of the antibodies of the invention in a suitable host cell, recovering the expressed polypeptides, which may be expressed together in a host cell, or separately in different host cells, and isolating antibodies.

30 A yet further aspect of the invention provides a method for treating, ameliorating or inhibiting pain in a canine or treating a tumour induced to proliferate by NGF, the

method comprising the step of administering to the canine an effective amount of a polynucleotide according to any of the foregoing aspects of the invention.

A yet further aspect of the invention provides an antibody or antibody binding  
5 fragment according to any of the foregoing aspects of the invention, or a pharmaceutical composition according to the foregoing aspects of the invention, or a nucleic acid or vector comprising the same according to any of the foregoing aspects of the invention for use in the treatment or prevention of pain in a canine.

10 In certain embodiments the pain is acute pain. In certain further embodiments, the pain is chronic pain. Furthermore, the pain may be post-operative pain, or pain resulting from any operating procedure which in canines may include, but is not limited to, orthopaedic surgery, soft tissue surgery, ovariohysterectomy  
15 procedures, castration procedures and the like. In certain further embodiments, the pain is chronic pain associated with cancer or a cancerous condition. In certain further embodiments, the pain is associated with, or resulting from, rheumatoid arthritis or osteoarthritis. In certain embodiments, the pain is inflammatory pain or pruritic pain.

20 A yet further aspect of the invention provides an antibody or antibody binding fragment according to any of the foregoing aspects of the invention, or a pharmaceutical composition according to the foregoing aspects of the invention, or a nucleic acid or vector comprising the same according to any of the foregoing aspects of the invention for use in the treatment of arthritis, in particular  
25 osteoarthritis and/or rheumatoid arthritis.

A yet further aspect of the invention provides an antibody or antibody binding fragment according to any of the foregoing aspects of the invention, or a pharmaceutical composition according to the foregoing aspects of the invention, or  
30 a nucleic acid or vector comprising the same according to any of the foregoing aspects of the invention for use in the treatment of a tumour induced to proliferate by NGF in a canine subject and conditions associated therewith, in particular

osteosarcoma. In certain embodiments, the tumour is induced to proliferate by autocrine or paracrine NGF.

5 A yet further aspect of the invention provides use of an antibody or antibody binding fragment according to any of the foregoing aspects of the invention, or a pharmaceutical composition according to the foregoing aspects of the invention, or a nucleic acid or vector comprising the same according to any of the foregoing aspects of the invention in the preparation of a medicament for the treatment or prevention of pain in a canine.

10 Typically the pain is chronic pain. Furthermore, the pain may be post-operative pain, or pain resulting from any operating procedure which in canines may include, but is not limited to, orthopaedic surgery, soft tissue surgery, ovariohysterectomy procedures, castration procedures and the like. In certain further embodiments, the pain is chronic pain associated with cancer or a cancerous condition. In  
15 certain further embodiments, the pain is associated with, or resulting from, rheumatoid arthritis or osteoarthritis. In certain embodiments, the pain is inflammatory pain or pruritic pain.

20 A yet further aspect of the invention provides use of an antibody or antibody binding fragment according to any of the foregoing aspects of the invention, or a pharmaceutical composition according to the foregoing aspects of the invention, or a nucleic acid or vector comprising the same according to any of the foregoing aspects of the invention in the preparation of a medicament for the treatment,  
25 inhibition amelioration or prevention of rheumatoid arthritis or osteoarthritis in a canine.

A yet further aspect of the invention provides use of an antibody or antibody binding fragment according to any of the foregoing aspects of the invention, or a  
30 pharmaceutical composition according to the foregoing aspects of the invention, or a nucleic acid or vector comprising the same according to any of the foregoing aspects of the invention in the preparation of a medicament for the treatment of a

tumour induced to proliferate by NGF in a canine and conditions associated therewith, in particular osteosarcoma. In certain embodiments, the tumour is induced to proliferate by autocrine or paracrine NGF.

- 5 In a yet further aspect there is provided a cell line, or a derivative or progeny cell thereof that produces anti-canine NGF neutralising monoclonal antibodies, or fragments thereof according to the invention.

10 A yet further aspect of the present invention provides a kit for the treatment of pain in canines, or for the treatment of a condition associated with pain, or for the treatment, amelioration or inhibition of pain associated with osteoarthritis or rheumatoid arthritis comprising an anti-canine NGF antibody or binding fragment according to any of the foregoing aspects of the invention and instructions for use of the same.

15 A yet further aspect of the present invention provides a diagnostic kit for the detection of an anti-canine NGF monoclonal antibody in fluids in vitro, ex vivo and in vivo, for use in determining the concentration of said antibody. The kit may comprise any of the antibodies of the invention or a binding fragment thereof. The  
20 kit may comprise instructions for use of same.

#### Brief Description of the Figures

Figure 1 is a graph showing the binding of caninised antibodies produced according to the invention to murine NGF and canine NGF.

25 Figure 2A-D shows a series of gels showing protein A purification of the caninised antibodies of the invention.

Figure 3 shows a gel showing the results of purification of caninised antibodies using SDS-Page.

30

Figure 4 shows a graph showing the inhibition of NGF induced proliferation of TF-1 cells by caninised antibodies.

5 Figure 5 shows a graph showing complement deposition induced by antigen-captured caninised antibodies.

10 Figure 6 shows the amino acid sequence of a light chain variable domain of the caninised anti-NGF (SEQ ID NO:1). The three CDR regions, identified according to Kabat numbering, are underlined. Asterisks above a specific residue indicate differences in the sequence between the caninised sequence and the amino acid sequence of the rat alphaD11 anti-murine NGF monoclonal antibody.

15 Figure 7 shows the amino acid sequence of a heavy chain variable domain of the caninised anti-NGF (SEQ ID NO:2). The three CDR regions, identified according to Kabat numbering, are underlined. Asterisks above a specific residue indicate differences in the sequence between the rat aD11 anti-murine NGF monoclonal antibody.

20 Figure 8 shows the amino acid sequence (SEQ ID NO:5) of a caninised anti-NGF light chain variable domain canine kappa light chain (caN-kLC) antibody. Variable domain residues are shown in bold.

25 Figure 9 shows the amino acid sequence (SEQ ID NO:6) of a caninised anti-NGF heavy chain variable domain canine IgG-A heavy chain (caN-HCA). Variable domain residues are shown in bold.

Figure 10 shows the amino acid sequence (SEQ ID NO:7) of a caninised anti-NGF heavy chain variable domain canine IgG-B heavy chain (caN-HCB). Variable domain residues are shown in bold.

Figure 11 shows the amino acid sequence (SEQ ID NO:8) of a caninised anti-NGF heavy chain variable domain canine IgG-C heavy chain (caN-HCC). Variable domain residues shown in bold.

5 Figure 12 shows the amino acid sequence (SEQ ID NO:9) of a caninised anti-NGF heavy chain variable domain canine IgG-D heavy chain (caN-HCD). Variable domain residues are shown in bold.

10 Figure 13A shows a graph showing the comparison of binding to NGF of anti-canine-NGF monoclonal antibodies using varying dilutions of SEQ ID No: 5 and 7 and SEQ ID No: 10 and 11. Figure 13B shows a graph showing complement deposition of the supernatants from Fig 13A.

15 Figure 14A shows a graph showing the comparison of binding to NGF of N-glycosylated and aglycosylated variants of anti-canine-NGF monoclonal antibodies with HCB and HCC heavy chain isotypes. Figure 14B shows a graph showing complement deposition of the supernatants from Fig 14A.

20 Figure 15A and B show the quantitative purification of the anti-canine NGF antibodies of the present invention using a three-step method (Method I) comprising (1) anion exchange chromatography, (2) hydrophobic interaction chromatography and (3) size exclusion chromatography. Figure 15A shows the results of fractionation by size exclusion HPLC. Figure 15B shows a reducing SDS-PAGE gel of fractions following each step. Figure 15C and D show the  
25 quantitative purification of the anti-canine NGF antibodies of the present invention using a two-step method (Method II) comprising Captopadhere chromatography and anion exchange chromatography. Figure 15C: SDS-PAGE analysis under non-reducing and reducing conditions. Lane 1 is MWS, lane 2 is 3450 sample 2  $\mu\text{g/mL}$  and 0  $\mu\text{l}$  reducing agent, lane 3 is 3450 sample 4  $\mu\text{g/mL}$  and 0  $\mu\text{l}$  reducing agent, lane 4 is 3450 sample 6  $\mu\text{g/mL}$  and 0  $\mu\text{l}$  reducing agent, lane 5 is MWS,  
30 lane 6 is 3450 sample 2  $\mu\text{g/mL}$  and 3  $\mu\text{l}$  reducing agent, lane 7 is 3450 sample 4

µg/mL and 3 µl reducing agent, lane 8 is 3450 sample 6 µg/mL and 3 µl reducing agent and lane 9 is MWS. Figure 15D: size exclusion chromatography.

Figure 16 shows a comparison of anti-NGF monoclonal antibody purified by Methods I and II. Figure 16A: comparison by non-reducing and reducing SDS-PAGE. Figure 16B: comparison by anti-NGF ELISA.

Figure 17 shows body weight (upper panel) and temperature (lower panel) are stable following intravenous administration of anti-canine NGF antibodies into dogs.

Figure 18 shows kinetic analysis of plasma anti-canine NGF monoclonal antibody concentration following intravenous injection to a dog. A beagle dog was injected intravenously with anti-NGF antibody at 2 mg/kg, samples of plasma were taken at the times indicated and anti-NGF monoclonal antibody was detected by NGF ELISA. The anti-canine NGF monoclonal antibody had a surprisingly long elimination (beta) phase half life of approximately 9 days.

Figure 19 shows that anti-canine NGF monoclonal antibodies reduce inflammatory pain in dogs. Kaolin was injected into the footpad of beagle dogs at Day -1, antibody or vehicle control at Day 0 and lameness was measured by a visual scoring scale.

#### Detailed description of the Invention

Following extensive experimentation, the inventor has taken the rat anti-mouse NGF monoclonal antibody (MAb) αD11 amino acid sequence and surprisingly used this to produce a non-immunogenic anti-canine NGF antibody. The resulting non-immunogenic antibody, which is not produced using standard CDR grafting techniques, is shown to exhibit high affinity binding to canine NGF. The antibody neutralises canine NGF biological function, most specifically by inhibiting the binding of NGF to cell based receptors TrkA and p75. Furthermore, it has also been discovered, unexpectedly, that when administered to a canine, neutralising



antibodies are not produced there against. Accordingly, the caninised antibody of the invention is suitable for long term chronic pain relief in dogs.

The process of generating the heavy and light chain variable domains for the antibodies of the invention which has been employed by the inventor results in the replacement of specific rat (donor) amino acid residues which are present within the framework regions of the light and heavy chain variable domains with residues which, based on the inventor's analysis, will retain the conformation of the CDR regions and therefore maintain binding specificity and avidity, while reducing the presence of immunogenic epitopes which may result in neutralising antibodies being generated against the antibody, if it were to be administered to canines in an unaltered form. Specifically, the method of preparing antibodies of the invention (known as PETisation) comprises assessing the sequence of the framework regions of a donor (e.g. rat) antibody for suitability for administering to a canine by comparing the sequence of the framework regions of the donor antibody with the sequence of an antibody or a pool of antibodies derived from canines. Although the comparison may be between the donor sequence and a single member of the target sequence, it will be obvious that comparison with a pool of target sequences is preferred because this will expand the number of natural options at each Kabat position in the target species. Not only will this increase the chance of a "match" between the donor and the target, but it will also expand the options for replacement where a match does not exist. As a result, a replacement with characteristics as close as possible to the donor will be able to be chosen. Where the donor sequence and the canine sequence differ at any Kabat number or corresponding position, the donor sequence is modified to substitute the amino acid residue in question with an amino acid residue which is known to be natural at that position in canines.

Where substitution of an amino acid residue present in a donor immunoglobulin framework region is required, typically this is undertaken using the principle of conservative substitution wherein an amino acid residue is replaced with an amino acid residue which is natural at that Kabat position in a canine and is as closely

related as possible in size, charge and hydrophobicity to the amino acid being substituted in the donor sequence. The intention is to choose a replacement which would cause no, or at least only minimum, perturbation or disruption to the three-dimensional structure of the donor antibody. In certain situations, there will be no clear option and each choice will have benefits and downsides. A final decision may require three-dimensional modelling or even expression of various alternative sequences. However, generally, a clear preference will be available. As a result of this procedure, a change in the donor sequence is only made when that residue would be foreign in the target and the replacement amino acid is as closely related as possible to that which it replaces. Thus, the creation of foreign epitopes is avoided, but the overall three-dimensional structure is preserved and as a result, affinity and specificity are also preserved.

The light and heavy chain constant regions are typically derived from canine (target) derived antibodies. The heavy chain constant domains are selected or modified such that they do not mediate downstream effector functions. As it has been found, quite surprisingly, that no or minimal neutralising antibodies are produced against the antibodies produced according to the invention, the antibodies have surprisingly been found to have the associated benefit of long circulatory half life and the option for repeat dosing. Furthermore, as the substitution of the framework residues is performed in such a manner that it does not affect the three dimensional conformation of the CDR regions, there will be no variation in binding specificity to the desired target.

There are four major IgG isotypes in man and mouse and while nomenclature is similar they differ in behaviour and function including affinity for bacterial products such as Protein A and Protein G, their ability to activate the complement dependent cytotoxicity (CDC) and their ability to induce killing of target cells through antibody dependent cellular cytotoxicity (ADCC). The selection of IgG isotypes with CDC and ADCC active or "armed" constant domains is considered to be of clinical benefit when antibodies are designed to eliminate target cells bearing their cognate antigen, such as in oncology or infection control (e.g. in human medical

use human IgG1 isotypes are preferred for the above purposes). By contrast, the activation of the immune system is considered undesirable in other settings such as in the relief of inflammation, pain or autoimmunity and so human IgG isotypes with minimal CDC and ADCC activity are preferred (e.g. in such human medical use, IgG4 isotypes are often preferred). Four distinct immunoglobulin gamma (IgG) heavy chain constant domain isotypes have been described in the canine immune system (US Patent No. 5,852,183, Tang L. et al. 2001. Veterinary Immunology and Immunopathology, 80. 259-270) along with single kappa and lambda constant domain sequences. The four canine heavy chain constant domains A, B, C and D have not been characterised in terms of functional activity mediated thereby. Despite overall homology to the IgG family, the proteins encoding canine IgG are more related to one another than to family members from other species, so it has not been possible by homology alone to define which of the above functions if any can be ascribed to each of the four canine isotypes. The selection of IgG isotypes with CDC and ADCC active constant domains is considered to be of benefit when antibodies are designed to eliminate target cells bearing the cognate antigen, such as in oncology or infection control, e.g. in human medical use human IgG1 isotypes are preferred. By contrast, the activation of the immune system is considered undesirable in other settings such as in the relief of inflammation, pain or autoimmunity and so human IgG isotypes with minimal or "disarmed" CDC and ADCC activity are preferred, e.g. in human medical use, IgG4 isotypes would be selected.

The antibodies of the invention comprise canine derived heavy and light chain constant domains. Furthermore, the complementarity determining regions are derived from the rat alphaD11 anti-mouse NGF antibody. The  $\alpha$ D11 antibody was first described by Cattaneo et al. (Cattaneo A, Rapposelli B, Calissano P. (1988) "Three distinct types of monoclonal antibodies after long-term immunization of rats with mouse nerve growth factor". J Neurochem 50(4):1003-1010). The alphaD11 antibody was subsequently cloned by Ruberti et al. (Ruberti, F. et al. (1993) "Cloning and Expression of an Anti-Nerve Growth Factor (NGF) Antibody for

Studies Using the Neuroantibody Approach". Cellular and Molecular Neurobiology. 13(5):559-568).

The CDR regions derived from the  $\alpha$ D11 antibody are combined with framework region sequences which have been determined by the inventor to preserve CDR tertiary structure, and therefore binding specificity, while preventing neutralising antibodies being raised there against, when the antibody is administered to a canine.

Each of the light and heavy chain variable regions contains four framework regions, referred to as FR1-FR4. For each of these framework regions, the inventor has identified a preferred amino residue (a so called preferred residue) for each specific position, and furthermore alternative amino acid residues which could also be provided at that position. Tables 1 to 8 below illustrate the 4 framework regions for each of the heavy and light chains. The tables provide the amino acid position relative to that specific framework region and further according to the Kabat numbering system used to identify the position of a particular residue along the length of the complete heavy or light chain variable domain. The residue or residues shown as group 1 residues are the preferred residues, while the group 2 residues are alternative residues. However these would generally not be preferable to the residues shown in group 1 relating to that specific position. The amino acid residues are identified using the single letter system.

Table 1 – Light chain variable domain FR1 residues

Light chain FR1 position	Kabat light chain numbering position	Group 1 amino acid residues	Group 2 amino acid residues
1	1	D	
2	2	I	
3	3	QV	

4	4	M	
5	5	TM	I
6	6	Q	
7	7	ST	
8	8	P	
9	9	AL	P
10	10	S	
11	11	L	
12	12	S	A
13	13	LV	
14	14	S	RT
15	15	QPR	
16	16	GE	D
17	17	E	D
18	18	TKP	AEL
19	19	VA	
20	20	TS	
21	21	I	
22	22	ST	Y
23	23	C	Y

Table 2 – Light chain variable domain FR2 residues

Light chain FR2 position	Kabat light chain numbering position	Group 1 amino acid residues	Group 2 amino acid residues
1	35	W	
2	36	YF	IL
3	37	QR	IL
4	38	Q	H
5	39	K	R

6	40	P	AS
7	41	G	D
8	42	Q	
9	43	SA	PT
10	44	P	
11	45	KQ	ER
12	46	LR	AGPS
13	47	L	
14	48	I	L
15	49	Y	EFNSV

Table 3 – Light chain variable domain FR3 residues

Light chain FR3 position	Kabat light chain numbering position	Group 1 amino acid residues	Group 2 amino acid residues
1	57	G	A
2	58	V	A
3	59	P	S
4	60	SD	
5	61	R	
6	62	F	LV
7	63	S	I
8	64	G	A
9	65	S	
10	66	G	
11	67	S	
12	68	G	
13	69	T	A
14	70	DE	
15	71	FY	

16	72	ST	R
17	73	FL	
18	74	KT	R
19	75	I	
20	76	SN	
21	77	S	
22	78	LV	
23	79	E	
24	80	PS	A
25	81	E	DGIN
26	82	D	
27	82A	VA	GST
28	82B	A	G
29	82C	V	IL
30	83	Y	
31	84	YF	
32	85	C	

Table 4 – Light chain variable domain FR4 residues

Light chain FR4 position	Kabat light chain numbering position	Group 1 amino acid residues	Group 2 amino acid residues
1	95	F	
2	96	G	S
3	97	A	PQT
4	98	G	E
5	99	T	P
6	100	K	QS
7	101	V	LW
8	102	ED	R

9	103	L	I
10	104	K	

Table 5 – Heavy chain variable domain FR1 residues

Heavy chain FR1 position	Kabat heavy chain numbering position	Group 1 amino acid residues	Group 2 amino acid residues
1	1	E	DG
2	2	V	EGILM
3	3	Q	AEHKLP RSV
4	4	L	PV
5	5	V	AELM
6	6	E	AQ
7	7	S	FLT
8	8	G	
9	9	G	E
10	10	GD	AENT
11	11	L	QRVW
12	12	V	AIM
13	13	QN	KR
14	14	P	FT
15	15	GT	AE
16	16	GE	A
17	17	ST	P
18	18	L	R
19	19	RT	GKV
20	20	L	IV
21	21	S	Y
22	22	C	



23	23	V	AEIL
24	24	AIV	GST
25	25	S	GPT
26	26	G	DRT
27	27	F	DILSTV
28	28	ST	ADILMN PR
29	29	LF	IMV
30	30	ST	DGHIKN RV

Table 6 – Heavy chain variable domain FR2 residues

Heavy Chain FR2 position	Kabat heavy chain numbering position	Group 1 Amino Acid residues	Group 2 Amino Acid residues
1	36	W	C
2	37	V	AFIL
3	38	R	
4	39	Q	HL
5	40	A	DGPSTV
6	41	LP	
7	42	G	ELR
8	43	RK	AEGMQ
9	44	G	DERTV
10	45	L	FMP
11	46	EQ	DHLPR
12	47	W	CFLMSY
13	48	V	FIL
14	49	GA	LST

Table 7 – Heavy chain variable domain FR3 residues

Heavy chain FR3 position	Kabat heavy chain numbering position	Group 1 amino acid residues	Group 2 amino acid residues
1	66	R	Q
2	67	LF	V
3	68	T	ALS
4	69	I	LMTV
5	70	ST	AF
6	71	R	K
7	72	D	EN
8	73	TN	DGIS
9	74	AS	DGPTV
10	75	K	EGMNQ R
11	76	SN	DHKKR
12	77	T	AIMS
13	78	VL	AIM
14	79	FY	HST
15	80	L	I
16	81	KQ	ADEHR
17	82	M	L
18	82A	HN	DKPRST
19	82B	S	DGNRT
20	82C	L	V
21	83	QR	GIKST
22	84	SA	DGPTV
23	85	E	ADV
24	86	D	

25	87	T	AMS
26	88	A	GV
27	89	TV	FIKLMQ
28	90	Y	H
29	91	Y	FH
30	92	C	
31	93	A	CGLMRS TV
32	94	RK	ADEGIL MNPQST V

Table 8 – Heavy chain variable domain FR4 residues

Heavy Chain FR4 position	Kabat heavy chain numbering position	Group 1 Amino Acid residues	Group 2 Amino Acid residues
1	103	W	L
2	104	G	AS
3	105	Q	DHPR
4	106	G	
5	107	T	AINS
6	108	SL	PQR
7	109	V	ILP
8	110	T	AFILPSY
9	111	V	A
10	112	S	ACPT
11	113	S	ALP

The caninised antibody of the invention therefore differs from, for example, a chimeric monoclonal antibody which consists of a complete variable region derived

from a first species and constant domains derived from a second species, or from a CDR-grafted caninised antibody, where the complementarity determining regions (CDRs) of the heavy and light chain variable regions comprise amino acid residues derived from a donor antibody and introduced into framework regions (FR) and constant regions (CR) derived from a target antibody or from canine germline sequences.

It is preferred that the caninised antibody substantially retains the binding properties of the parent (donor) antibody from which the CDRs are derived. That means that the caninised antibody will exhibit the same or substantially the same antigen-binding affinity and avidity as the donor antibody from which the CDRs are derived. Ideally, the affinity of the caninised antibody will not be less than 10% of the donor antibody affinity for the target epitope, more preferably not less than about 30%, and most preferably the affinity will not be less than 50% of the parent (donor) antibody. Methods for assaying antigen-binding affinity are well known in the art and include half-maximal binding assays, competition assays, and Scatchard analysis.

As defined hereinbefore, the present invention extends to binding members or antigen binding fragments derived from the caninised antibodies of the invention. Such antigen binding fragments refer to one or more fragments of an antibody that retain the ability to specifically bind to canine NGF. It has been shown that the antigen binding function of an antibody can be performed by fragments of a full length antibody. In certain embodiments, the binding members or antigen binding fragments may be isolated binding members. A binding member or antigen binding fragment of the invention may comprise a fragment of the antibodies of the present invention, e.g. a fragment of a fully caninised antibody molecule, such as the heavy or light chain only, or, for example, the variable domain of the heavy and/or light chain. In certain embodiments, a binding member may typically comprise, consist, or consist essentially of an antibody VH and/or VL domain. VH domains of binding members are also provided as part of the invention. Within each of the VH and VL domains are 3 complementarity determining regions

("CDRs"), along with 4 associated framework regions ("FRs"). A VH domain typically comprises 3 HCDRs (heavy chain complementarity determining regions), and a VL domain typically comprises 3 LCDRs (light chain complementarity regions). Accordingly, a binding member may comprise a VH domain comprising, in sequence, VH CDR1 (or HCDR1), CDR2 (HCDR2) and CDR3 (HCDR3) regions along with a plurality of associated framework regions. A binding member may additionally or alternatively comprise a VL domain comprising VL CDR1, CDR2 and CDR3 domains along with associated framework regions. The VH or VL domains typically comprise four framework regions, FR1, FR2, FR3 and FR4. As used herein, the term "framework region" or "framework sequence" refers to the remaining sequences of a variable region minus the CDRs. Because the exact definition of a CDR sequence can be determined by different systems (Kabat, Chothia etc.), the meaning of a framework sequence is subject to correspondingly different interpretations. The six CDRs (VL-CDR1, CDR2 and CDR3 of the light chain and VH-CDR1, CDR2 and CDR3 of the heavy chain) divide the framework regions on the light chain and the heavy chain into four sub-regions known as FR1, FR2, FR3 and FR4 on each chain.

Figure 6 shows the amino acid sequence of a light chain variable domain of an anti-NGF antibody according to the invention. The CDR1, CDR2 and CDR3 regions are underlined. As such, and as shown in Figures 6 the VL-CDR1 is positioned between FR1 and FR2 framework regions, the VL-CDR2 is positioned between the FR2 and FR3 framework regions, and the VL-CDR3 is positioned between the FR3 and FR4 framework regions. Figure 7 shows the amino acid sequence of a heavy chain variable domain of an anti-NGF antibody according to the invention. The CDR1, CDR2 and CDR3 regions are underlined. As with the light chain variable region shown in Figure 6, the VH-CDR1 is positioned between FR1 and FR2 framework regions, the VH-CDR2 is position between the FR2 and FR3 framework regions, and the VH-CDR3 is positioned between the FR3 and FR4 framework regions.

In Figures 6 and 7, the residues of the light chain variable domain (Figure 6) and heavy chain variable domain (Figure 7) are conventionally numbered according to the numbering system devised by Kabat et al. (Kabat, E.A., Wu, T.T., Perry, H., Gottesman, K. and Foeller, C. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition. NIH Publication No. 91-3242, Kabat et al. (1971) Ann. NY Acad. Sci. 190:382-391). The Kabat numbering system refers to a system of numbering amino acid residues which are more variable (i.e. hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen binding portion thereof. The Kabat numbering system is therefore generally used when referring to a residue in the variable domain (approximately residues 1-104 of the light chain and residues 1-113 of the heavy chain). This numbering system may be used in the present specification, where stated. The Kabat residue designations do not always correspond directly with the linear numbering of the amino acid residues of the heavy and light chain variable regions of the present invention provided in the relevant sequences listed herein. In particular, the actual linear amino acid sequence may contain fewer or additional amino acids than in the strict Kabat numbering corresponding to a shortening of, or insertion into, a structural component, whether a framework region or complementarity determining region (CDR), of the basic variable domain structure of the heavy or light chain. The correct Kabat numbering of residues may be determined for any given antibody by alignment of residues in the sequence of the antibody with a standard sequence to which the Kabat numbering has been applied.

Furthermore, Figure 7 shows a heavy chain variable domain amino acid sequence. This is also shown in SEQ ID NO:2. However, in Figure 7, the numbering takes account of amino acid residues 80, 80A, 80B, and 80C, whereas in SEQ ID NO:2, the numbering continues sequentially, that is 80, 81, 82 and 83. The same is true for Kabat residues 100, 100A, 100B, 100C, 100D, 100E and 100F in Figure 7.

As described hereinbefore, an antibody binding fragment may be selected from the group comprising, but not limited to, a Fab fragment, a Fab' fragment and a scFv (single chain variable fragment), or from a peptidomimetic, a diabody, or a related multivalent derivative.

5

In certain embodiments the antibody binding fragment is a Fab, or F(ab')<sub>2</sub> fragment, which consists of the VL, VH, CL and CH1 domains of an antibody. In certain embodiments, the VL domain has an amino acid sequence of SEQ ID NO:1 or SEQ ID NO:3, and the VH domain has an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4. In certain embodiments, the CL and CH1 domains are based on the amino acid sequence of a CL and CH1 domain of a canine immunoglobulin.

10

Techniques used for the recombinant production of Fab, Fab' and F(ab')<sub>2</sub> fragments are well known to the person skilled in the art and include those disclosed in International PCT Patent Publication WO 92/22324, and in Sawai et al., "Direct Production of the Fab Fragment Derived From the Sperm Immobilizing Antibody Using Polymerase Chain Reaction and cDNA Expression Vectors", 1995, AJRI 34:26-34. Examples of techniques which can be used to produce scFv (single chain Fv fragments) are disclosed in Huston et al., "Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins", *Methods in Enzymology*, vol. 203:46-88 (1991).

15

20

In certain embodiments, antibody fragments can be derived from full length antibodies by proteolytic digestion according to the method of Morimoto (Morimoto et al., "Single-step purification of F(ab')<sub>2</sub> fragments of mouse monoclonal antibodies (immunoglobulins G1) by hydrophobic interaction high performance liquid chromatography using TSKgel Phenyl-5PW" *Journal of Biochemical and Biophysical Methods* 24:107-117 (1992)). Antibody fragments can also be produced directly by host cells (Carter et al., "High level Escherichia coli expression and production of a bivalent humanized antibody fragment" *Bio/Technology* 10:163-167 (1992)).

25

30

In addition to providing a caninised monoclonal antibody which has binding specificity to canine NGF and which antagonises canine NGF function, the present invention further extends to binding members other than antibodies comprising a pair of binding domains based on the amino acid sequence of a VL (light chain variable) region as defined in SEQ ID NO:1 or SEQ ID NO:3 and an amino acid sequence of a VH (heavy chain variable) region as defined in SEQ ID NO:2 or SEQ ID NO:4. In particular, the invention extends to single binding domains which are based on either the VL or VH region of the caninised antibodies of the antibodies of the invention.

Accordingly, in certain further embodiments of the present invention, there is provided a binding member comprising, consisting or consisting essentially of a single binding domain derived from the humanised antibody of the invention. In certain embodiments, the single binding domain is derived from the amino acid sequence of the VH (heavy chain variable domain) as defined in SEQ ID NO:2 or SEQ ID NO:4. Such a binding domain may be used as a targeting agent to canine NGF.

In certain embodiments, further engineering techniques can be used to modify the antibodies of the present invention, for example by including modifications of the Fc region which can alter serum half life, complement fixation, Fc receptor binding and/or antigen dependent cellular cytotoxicity. Further, in certain embodiments, antibodies or antibody fragments can be produced which have altered glycosylation patterns. In certain embodiments, an antibody of the invention is altered to increase or decrease the extent to which the antibody is glycosylated. Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of a carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X -threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences



in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N- acetylglactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used. The inventor has provided  
5 aglycosylated canine constant domains, these being defined herein as SEQ ID NO:15, 16, 17, 18, 19, 20, 21, and 22.

In certain further embodiments, the anti-canine NGF antibodies of the invention can be PEGylated by reacting the antibody with a polyethylene glycol (PEG)  
10 derivative. In certain embodiments, the antibody is defucosylated and therefore lacks fucose residues.

In certain embodiments, modifications in the biological properties of an antibody may be accomplished by selecting substitutions that affect (a) the structure of the  
15 polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Amino acids may be grouped according to similarities in the properties of their side chains (A. L. Lehninger, in Biochemistry, 2<sup>nd</sup> Ed., 73-75, Worth Publishers, New York (1975)): (1) non-polar: Ala (A), Val (V),  
20 Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M); (2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q); (3) acidic: Asp (D), Glu (E); (4) basic: Lys (K), Arg (R), His(H). Alternatively, naturally occurring residues may be divided into groups based on common side-chain properties: (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;  
25 (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe. Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, into the remaining (e.g., non-conserved) sites.

30 In various further aspects, the present invention extends to an immunoconjugate comprising an anti-canine NGF antibody of the invention, or an antigen binding

portion thereof linked to a partner molecule. In certain embodiments, such an antibody-partner molecule conjugate is conjugated by means of a chemical linker, such as a peptidyl linker, a hydrazine linker or a disulphide linker. In certain embodiments, the coupling partner is an effector molecule, label, drug, or carrier molecule. Suitable techniques for coupling the antibodies of the invention to both peptidyl and non-peptidyl coupling partners will be well known to persons skilled in the art. Examples of suitable labels include detectable labels, such as a radiolabel, or an enzymatic label, such as horse radish peroxidase, or chemical moieties, such as biotin. Alternatively, the label may be a functional label, for example, ricin, or pro-drugs which are capable of converting prodrugs into active drugs at the site of antibody binding.

In various further aspects, the present invention extends to polynucleotides, and in particular isolated polynucleotides, which encode the caninised antibodies, antibody fragments and binding members of the present invention. As defined herein, a "polynucleotide" includes any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA, or modified RNA or DNA, including without limitation, single and double stranded RNA, and RNA which is a mixture of single and double stranded regions. A polynucleotide of the invention, e.g. a polynucleotide which encodes a polypeptide or polypeptides of the invention includes allelic variants thereof and/or their complements including a polynucleotide that hybridises to such nucleotide sequences under conditions of moderate or high stringency.

The present invention further extends to antibody mimetics, such as domain antibodies, nanobodies, unibodies, versabodies, and duocalins which are based on the canine NGF antibodies of the present invention. A wide variety of antibody mimetic technologies are known to the person skilled in the art. For example, so called, domain antibodies (Domantis, UK) are small functional binding units of antibodies which correspond to the variable regions of either the light or heavy chains of human antibodies. Directions for the production of such domain antibodies can be found in US Patent No. 6,291,158, US Patent No. 6,582,915

and US Patent No. 6,593,081. Nanobodies are antibody-derived therapeutic proteins which contain unique structural and functional properties of naturally occurring heavy chain antibodies found in camelids. Unibodies are a further antibody fragment technology, based upon the removal of the hinge region of IgG4 antibodies. The deletion of the hinge region results in a molecule which is approximately half the size of a traditional IgG4 antibody and which has a univalent binding region. Unibodies preserve the property of IgG4 antibodies of being inert and therefore not inducing immune responses.

Further binding molecules include affibody molecules (US Patent 5,831,012), DARPins (designed ankyrin repeat proteins) (International PCT Patent Application Publication WO 02/20565) and anticalins (US Patent No. 7,250,297 and WO 99/16873). Verabodies are a further antibody mimetic technology. Versabodies (Amunix, US Patent Application Publication No. 2007/0191272) are small proteins, referred to as microproteins, of 3-5kDa with greater than 15% cysteine residues, which form a high disulphide bond density scaffold which replaces the hydrophobic core which protein typically exhibit

Avimers are another type of antibody mimetic. Avimers originate from the recombination of families of human serum proteins. They are single protein chains composed of modular binding domains, each of which is designed to bind to a particular target site. The avimers can bind simultaneously to sites on a single protein target and/or sites on multiple protein targets. Known as multi-point attachment or avidity, this binding mechanism mimics the way cells and molecules interact in the body, supports the generation of antagonists and agonists, and results in drugs with multiple functions and potent activity. Avimers libraries can be produced according to WO 2004/044011 and for example US 2005/0053973. Avimers libraries are also available commercially from Avidia Inc, Mountain View, California, USA.

*Antibody production*

The antibodies and binding members of the invention may be produced wholly or partly by chemical synthesis. For example, the antibodies and binding members of the invention can be prepared by techniques which are well known to the person skilled in the art, such as standard liquid peptide synthesis, or by solid-  
5 phase peptide synthesis methods. Alternatively, the antibodies and binding members may be prepared in solution using liquid phase peptide synthesis techniques, or further by a combination of solid-phase, liquid phase and solution chemistry.

10 The present invention further extends to the production of the antibodies or binding members of the invention by expression of a nucleic acid which encodes at least one amino acid which comprises an antibody of the invention in a suitable expression system, such that a desired peptide or polypeptide can be encoded. For example, a nucleic acid encoding the amino acid light chain and a second  
15 nucleic acid encoding an amino acid heavy chain can be expressed to provide an antibody of the present invention.

Accordingly, in certain further aspects of the invention, there is provided nucleic acids encoding amino acid sequences which form the antibodies or binding  
20 members of the present invention.

Typically, nucleic acids encoding the amino acid sequences which form antibodies or binding members of the present invention can be provided in an isolated or purified form, or provided in a form which is substantially free of material which can  
25 be naturally associated with it, with the exception of one or more regulatory sequences. Nucleic acid which expresses an antibody or binding member of the invention may be wholly or partially synthetic and may include, but is not limited to DNA, cDNA and RNA.

30 Nucleic acid sequences encoding the antibodies or binding members of the invention can be readily prepared by the skilled person using techniques which are well known to those skilled in the art, such as those described in Sambrook et al.

“Molecular Cloning”, A laboratory manual, cold Spring Harbor Laboratory Press, Volumes 1-3, 2001 (ISBN-0879695773), and Ausubel et al. Short Protocols in Molecular Biology. John Wiley and Sons, 4<sup>th</sup> Edition, 1999 (ISBN – 0471250929). Said techniques include (i) the use of the polymerase chain reaction (PCR) to  
5 amplify samples of nucleic acid, (ii) chemical synthesis, or (iii) preparation of cDNA sequences. DNA encoding antibodies or binding members of the invention may be generated and used in any suitable way known to those skilled in the art, including taking encoding DNA, identifying suitable restriction enzyme recognition sites either side of the portion to be expressed, and cutting out said portion from  
10 the DNA. The excised portion may then be operably linked to a suitable promoter and expressed in a suitable expression system, such as a commercially available expression system. Alternatively, the relevant portions of DNA can be amplified by using suitable PCR primers. Modifications to the DNA sequences can be made by using site directed mutagenesis.

15 Nucleic acid sequences encoding the antibodies or binding members of the invention may be provided as constructs in the form of a plasmid, vector, transcription or expression cassette which comprises at least one nucleic acid as described above. The construct may be comprised within a recombinant host cell  
20 which comprises one or more constructs as above. Expression may conveniently be achieved by culturing, under appropriate conditions, recombinant host cells containing suitable nucleic acid sequences. Following expression, the antibody or antibody fragments may be isolated and/or purified using any suitable technique, then used as appropriate.

25 Systems for cloning and expression of a polypeptide in a variety of different host cells are well known. Suitable host cells include bacteria, mammalian cells, yeast, insect and baculovirus systems. Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary (CHO)  
30 cells, HeLa cells, baby hamster kidney cells and NS0 mouse myeloma cells. A common, preferred bacterial host is *E. coli*. The expression of antibodies and antibody fragments in prokaryotic cells such as *E. coli* is well established in the art.

Expression in eukaryotic cells in culture is also available to those skilled in the art as an option for production of a binding member.

General techniques for the production of antibodies are well known to the person skilled in the field, with such methods being discussed in, for example, Kohler and Milstein (1975) Nature 256: 495-497; US Patent No. 4,376,110; Harlow and Lane, Antibodies: a Laboratory Manual, (1988) Cold Spring Harbor. Techniques for the preparation of recombinant antibody molecules are described in the above references and also in, for example, European Patent Number 0,368,684.

In certain embodiments of the invention, recombinant nucleic acids comprising an insert coding for a heavy chain variable domain and/or for a light chain variable domain of antibodies or binding members are employed. By definition, such nucleic acids comprise encode single stranded nucleic acids, double stranded nucleic acids consisting of said coding nucleic acids and of complementary nucleic acids thereto, or these complementary (single stranded) nucleic acids themselves.

Furthermore, nucleic acids encoding a heavy chain variable domain and/or a light chain variable domain of antibodies can be enzymatically or chemically synthesised nucleic acids having the authentic sequence coding for a naturally-occurring heavy chain variable domain and/or for the light chain variable domain, or a mutant thereof.

An antibody of the invention may be produced by recombinant means, not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which is preferably a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. The heterologous signal sequence selected preferably is one that is recognized and processed (i.e., cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not recognize and process a native antibody signal sequence, the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the

group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders.

5 The term "isolated", when used in reference to the caninised antibodies of the invention, or to binding members derived therefrom, or polypeptides which encode the same, refers to the state in which said antibodies, binding members or nucleic acids (polynucleotides) are provided in an isolated and/or purified form, that is they have been separated, isolated or purified from their natural environment, and are provided in a substantially pure or homogeneous form, or, in the case of nucleic acid, free or substantially free of nucleic acid or genes of origin other than the sequence encoding a polypeptide with the required function. Accordingly, such isolated antibodies, binding members and isolated nucleic acids will be free or substantially free of material with which they are naturally associated, such as other polypeptides or nucleic acids with which they are found in their natural environment, or the environment in which they are prepared (e.g. cell culture) when such preparation is by recombinant DNA technology practised in vitro or in vivo.

20 Antibodies, binding members and nucleic acids may be formulated with diluents or adjuvants and still, for practical purposes, be considered as being provided in an isolated form. For example the antibodies and binding members can be mixed with gelatin or other carriers if used to coat microtitre plates for use in immunoassays, or will be mixed with pharmaceutically acceptable carriers or diluents when used in diagnosis or therapy. The antibodies or binding members may be glycosylated, either naturally or by systems of heterologous eukaryotic cells (e.g. CHO or NSO cells, or they may be (for example if produced by expression in a prokaryotic cell) unglycosylated.

30 Heterogeneous preparations comprising anti-canine NGF caninised antibody molecules also form part of the invention. For example, such preparations may be mixtures of antibodies with full-length heavy chains and heavy chains lacking the C-terminal lysine, with various degrees of glycosylation and/or with derivatized

amino acids, such as cyclization of an N-terminal glutamic acid to form a pyroglutamic acid residue.

#### *Purification of Antibodies*

5 Canine anti-NGF MAbs isotypes A, B, C and D are equipotent. Canine IgG isotypes A and D may be preferred for use in the present invention as these isotypes have a desirable lack of binding to complement. However, these isotypes do not bind Staphylococcus Protein A or Streptococcal Protein G and so cannot be purified using these common tools. The inventors of the present invention have  
10 identified two alternative methods which can be used to purify isotypes A and/or D. The first method comprises a combination of anion exchange chromatography, hydrophobic interaction chromatography and size exclusion chromatography. The second method comprises a combination of captoadhere affinity chromatography and anion exchange chromatography.

15

#### *Pharmaceutical compositions*

Typically the pharmaceutical compositions of the invention are formulated in a liquid formulation, a lyophilized formulation, a lyophilized formulation that is reconstituted as a liquid, or as an aerosol formulation. In certain embodiments,  
20 the antibody in the formulation is at a concentration of: about 0.5 mg/ml to about 250 mg/ml, about 0.5 mg/ml to about 45 mg/ml, about 0.5 mg/ml to about 100 mg/ml, about 100 mg/ml to about 200 mg/ml, or about 50 mg/ml to about 250 mg/ml.

25 In certain embodiments, the formulation further comprises a buffer. Typically the pH of the formulation is from about pH 5.5 to about pH 6.5. In certain embodiments, the buffer may comprise from about 4 mM to about 60 mM histidine buffer, about 5 mM to about 25 mM succinate buffer, or about 5 mM to 25 mM acetate buffer. In certain embodiments, the buffer comprises sodium chloride at a  
30 concentration of from about 10mM to 300mM, typically at around 125mM concentration and sodium citrate at a concentration of from about 5mM to 50mM, typically 25mM. In certain embodiments the formulation can further comprise a



surfactant at a concentration of just above 0% to about 0.2%. In certain embodiments the surfactant is selected from the group consisting of, but not limited to: polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-65, polysorbate-80, polysorbate-85, and combinations thereof. In a preferred embodiment, the surfactant is polysorbate-20 and may further comprise sodium chloride at a concentration of about 125mM and sodium citrate at a concentration of about 25mM.

### *Administration*

The antibodies or binding members of the present invention may be administered alone but will preferably be administered as a pharmaceutical composition which will generally comprise a suitable pharmaceutically acceptable excipient, diluent or carrier selected depending on the intended route of administration. Examples of suitable pharmaceutical carriers include; water, glycerol, ethanol and the like.

The monoclonal antibody or binding member of the present invention may be administered to a canine patient in need of treatment via any suitable route. Typically, the composition can be administered parenterally by injection or infusion. Examples of preferred routes for parenteral administration include, but are not limited to; intravenous, intracardial, intraarterial, intraperitoneal, intramuscular, intracavity, subcutaneous, transmucosal, inhalation or transdermal. Routes of administration may further include topical and enteral, for example, mucosal (including pulmonary), oral, nasal, rectal.

In embodiments where the composition is delivered as an injectable composition, for example in intravenous, intradermal or subcutaneous application, the active ingredient can be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as sodium chloride injection, Ringer's injection or, Lactated Ringer's injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

The composition may also be administered via microspheres, liposomes, other microparticulate delivery systems or sustained release formulations placed in certain tissues including blood.

5

Examples of the techniques and protocols mentioned above and other techniques and protocols which may be used in accordance with the invention can be found in Remington's Pharmaceutical Sciences, 18th edition, Gennaro, A.R., Lippincott Williams & Wilkins; 20th edition ISBN 0-912734-04-3 and Pharmaceutical Dosage  
10 Forms and Drug Delivery Systems; Ansel, H.C. et al. 7th Edition ISBN 0-683305-72-7.

The antibodies and compositions of the invention are typically administered to a subject in a "therapeutically effective amount", this being an amount sufficient to  
15 show benefit to the subject to whom the composition is administered. The actual dose administered, and rate and time-course of administration, will depend on, and can be determined with due reference to, the nature and severity of the condition which is being treated, as well as factors such as the age, sex and weight of the subject being treated, as well as the route of administration. Further  
20 due consideration should be given to the properties of the composition, for example, its binding activity and in-vivo plasma life, the concentration of the antibody or binding member in the formulation, as well as the route, site and rate of delivery.

25 Dosage regimens can include a single administration of the antibody or composition of the invention, or multiple administrative doses of the antibody or composition. The antibody or antibody containing compositions can further be administered sequentially or separately with other therapeutics and medicaments which are used for the treatment of the condition for which the antibody or binding  
30 member of the present invention is being administered to treat.

Examples of dosage regimens which can be administered to a subject can be selected from the group comprising, but not limited to; 1µg/kg/day through to 20mg/kg/day, 1µg/kg/day through to 10mg/kg/day, 10µg/kg/day through to 1mg/kg/day. In certain embodiments, the dosage will be such that a plasma concentration of from 1µg/ml to 100µg/ml of the antibody is obtained. However, the actual dose of the composition administered, and rate and time-course of administration, will depend on the nature and severity of the condition being treated. Prescription of treatment, e.g. decisions on dosage etc, is ultimately within the responsibility and at the discretion of veterinary practitioners and other veterinary doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners.

#### Definitions

Unless otherwise defined, all technical and scientific terms used herein have the meaning commonly understood by a person who is skilled in the art in the field of the present invention. The meaning and scope of the terms should be clear, however, in the event of any ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition.

Throughout the specification, unless the context demands otherwise, the terms "comprise" or "include", or variations such as "comprises" or "comprising", "includes" or "including" will be understood to imply the inclusion of a stated integer or group of integers, but not the exclusion of any other integer or group of integers.

As used herein, terms such as "a", "an" and "the" include singular and plural referents unless the context clearly demands otherwise. Thus, for example, reference to "an active agent" or "a pharmacologically active agent" includes a single active agent as well as two or more different active agents in combination, while references to "a carrier" includes mixtures of two or more carriers as well as a single carrier, and the like. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

As herein defined, the term “pain” means an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage.

5

In relation to operative or post-operative pain, the US Animal Welfare Act (Animal Welfare Act 2002. AWA regulations, CFR, Title 9 (Animals and Animal Products), Chapter 1 (Animal and Plant Health Inspection Service, Department of Agriculture). Subchapter A (Animal Welfare), Parts 1–4) defines a painful procedure as any procedure that would reasonably be expected to cause more than slight or momentary pain or distress in a human being to which that procedure was applied, that is, pain in excess of that caused by injections or other minor procedures. Therefore, if a canine undergoes a painful surgical procedure, the animal should receive postoperative analgesics.

10

15

In further instance, a canine may be experiencing significant or chronic pain as a result of an associated medical condition such as rheumatoid arthritis, osteoarthritis, inflammation or a cancerous or malignant condition.

20

The term “nociception” refers to the perception of noxious stimuli. As herein defined “neuropathic pain” (also known as 'neuralgia') is a pain that comes from problems with signals from the nerves. It may arise as a consequence of a lesion or disease affecting the somatosensory system. There are causes of neuropathic pain and it may be associated with abnormal sensations called dysesthesia, which occur spontaneously. Alternatively, it may be associated with allodynia which results when the pain comes on, or gets worse, with a touch or stimulus that would not normally cause pain. For example, a slight touch on the face may trigger pain if you have trigeminal neuralgia, or the pressure of the bedclothes may trigger pain if you have diabetic neuropathy. Neuropathic pain may also result from allodynia, where the pain comes on, or gets worse, with a touch or stimulus that would not normally cause pain. For example, a slight touch to the face may trigger pain if a subject has trigeminal neuralgia. Neuropathic pain relating to hyperalgesia means

25

30

that severe pain results from a stimulus or touch that would normally cause only slight discomfort, while paresthesia means that uncomfortable or painful feelings occur even when there is nothing in contact with the area causing the pain, for example pins and needles. Other forms of neuropathic pain involve pruritis or itch, which can be associated with allergic or inflammatory responses in the skin and inflammatory pain resulting from tissue damage and repair processes.

As defined herein, the term "NGF neutralising antibody" or similar describes an antibody that is capable of neutralising the biological activation and signalling of NGF. The neutralising antibody, which may also be referred to as an antagonistic antibody, or a blocking antibody, specifically, and preferably selectively, binds to NGF and inhibits one or more biological activities of NGF. For example, the neutralising antibody may inhibit the binding of a NGF to its target ligand, such as the cell membrane bound TrkA or p75 receptors.

As used herein, the term "biological activity" refers to any one or more inherent biological properties of a molecule (whether present naturally as found in vivo, or provided or enabled by recombinant means). Biological properties include but are not limited to receptor binding and/or activation; induction of cell signalling or cell proliferation, inhibiting cell growth, induction of cytokine production, induction of apoptosis, and enzymatic activity.

The term "complementarity determining region (CDR)", as used herein, refers to amino acid sequences which together define the binding affinity and specificity of the natural Fv region of a native immunoglobulin binding site as delineated by Kabat et al. (Kabat,E.A., Wu,T.T., Perry,H., Gottesman,K. and Foeller,C. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition. NIH Publication No. 91-3242). The term "framework region (FR)", as used herein, refers to amino acid sequences interposed between CDRs. These portions of the antibody serve to hold the CDRs in appropriate orientation (allows for CDRs to bind antigen).

The term “constant region (CR)” as used herein, refers to the portion of the antibody molecule which confers effector functions. In the present invention, constant regions typically mean canine constant regions, that is that the constant regions of the subject caninised antibodies are derived from canine immunoglobulins. The heavy chain constant region can be selected from any of the four isotypes: A, B, C or D.

The term “chimeric antibody” as used herein refers to an antibody containing sequences derived from two different antibodies, which typically are of different species. Most typically chimeric antibodies comprise variable domains derived from a donor species which bind specifically to a target epitope and constant domains derived from antibodies obtained from the target species to whom the antibody is to be administered.

The term “immunogenicity” as used herein refers to a measure of the ability of a targeting protein or therapeutic moiety to elicit an immune response (humoral or cellular) when administered to a recipient. The present invention is concerned with the immunogenicity of the subject caninised antibodies. Preferably the antibodies of the present invention have no immunogenicity, that is that no neutralising antibodies will be raised against them when administered to a canine, and further, no effector functions are mediated by the Fc regions of the antibody.

The term “identity” or “sequence identity” as used herein, means that at any particular amino acid residue position in an aligned sequence, the amino acid residue is identical between the aligned sequences. The term “similarity” or “sequence similarity” as used herein, indicates that, at any particular position in the aligned sequences, the amino acid residue is of a similar type between the sequences. For example, leucine may be substituted for an isoleucine or valine residue. This may be referred to as conservative substitution. Preferably when the amino acid sequences of the invention are modified by way of conservative substitution of any of the amino acid residues contained therein, these changes

have no effect on the binding specificity or functional activity of the resulting antibody when compared to the unmodified antibody.

Sequence identity with respect to a (native) polypeptide of the invention and its functional derivative relates to the percentage of amino acid residues in the candidate sequence which are identical with the residues of the corresponding native polypeptide, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percentage homology, and not considering any conservative substitutions as part of the sequence identity. Neither N- or C-terminal extensions, nor insertions shall be construed as reducing sequence identity or homology. Methods and computer programs for performing an alignment of two or more amino acid sequences and determining their sequence identity or homology are well known to the person skilled in the art. For example, the percentage of identity or similarity of 2 amino acid sequences can be readily calculated using algorithms e.g. BLAST (Altschul et al. 1990), FASTA (Pearson & Lipman 1988), or the Smith-Waterman algorithm (Smith & Waterman 1981).

As used herein, reference to an amino acid residue having the “highest homology” to a second amino acid residue refers to the amino acid residue which has the most characteristics or properties in common with the second amino acid residue. In determining whether an amino acid residue has the highest homology to a second amino acid residue, an assessment may typically be made of factors such as, but not limited to, charge, polarity, hydrophobicity, side arm mass and side arm dimension.

The term “corresponding position” as used herein to refer to an amino acid residue that is present in a second sequence at a position corresponding to a specified amino acid residue in a first sequence is intended to refer to the position in the second sequence which is the same position as the position in the first sequence when the two sequences are aligned to allow for maximum sequence identity between the two sequences. Amino acid residues at corresponding positions have the same Kabat numbering.

The term "consists essentially of" or "consisting essentially of" as used herein means that a polypeptide may have additional features or elements beyond those described provided that such additional features or elements do not materially  
5 affect the ability of the antibody or antibody fragment to have binding specificity to canine NGF. That is, the antibody or antibody fragments comprising the polypeptides may have additional features or elements that do not interfere with the ability of the antibody or antibody fragments to bind to canine NGF and antagonise canine NGF functional activity. Such modifications may be introduced  
10 into the amino acid sequence in order to reduce the immunogenicity of the antibody. For example, a polypeptide consisting essentially of a specified sequence may contain one, two, three, four, five or more additional, deleted or substituted amino acids, at either end or at both ends of the sequence provided that these amino acids do not interfere with, inhibit, block or interrupt the role of  
15 the antibody or fragment in binding to canine NGF and sequestering its biological function. Similarly, a polypeptide molecule which contributes to the canine NGF antagonistic antibodies of the invention may be chemically modified with one or more functional groups provided that such functional groups do not interfere with the ability of the antibody or antibody fragment to bind to canine NGF and  
20 antagonise its function.

As used herein, the term "effective amount" or "therapeutically effective amount" means the amount of an agent, binding compound, small molecule, fusion protein or peptidomimetic of the invention which is required to suppress canine NGF  
25 binding to the p75 and/or TrkA receptors.

The terms "polypeptide", "peptide", or "protein" are used interchangeably herein to designate a linear series of amino acid residues connected one to the other by peptide bonds between the alpha-amino and carboxy groups of adjacent residues.  
30 The amino acid residues are usually in the natural "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property is retained by the polypeptide.



As herein defined an "antibody" encompasses antigen-binding proteins which specifically bind to a target antigen of interest, in this case canine nerve growth factor, having one or more polypeptides that can be recombinantly prepared or which are genetically encodable by immunoglobulin genes, or fragments of immunoglobulin genes. The term "antibody" encompasses monoclonal and chimeric antibodies, in particular caninised antibodies, and further encompasses polyclonal antibodies or antibodies of any class or subtype. An "antibody" further extends to hybrid antibodies, bispecific antibodies, heteroantibodies and to functional fragments thereof which retain antigen binding.

The phrase "specifically binds to" refers to the binding of an antibody to a specific protein or target which is present amongst a heterogeneous population of proteins. Hence, when present in specific immunoassay conditions, the antibodies bind to a particular protein, in this case canine NGF, and do not bind in a significant amount to other proteins present in the sample.

As defined herein, a "canine" may also be referred to as a "dog". Canines can be categorised as belonging to the subspecies with the trinomial name *Canis lupus familiaris* (*Canis familiaris domesticus*) or *Canis lupus dingo*. Canines include any species of dog and includes both feral and pet varieties, the latter also being referred to as companion animals.

The present invention will now be described with reference to the following examples which are provided for the purpose of illustration and are not intended to be construed as being limiting on the present invention. The methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated.

## EXAMPLES

### Example 1 – Production of antibodies

Whole antibody sequences were produced by combining caninised variable domain sequences with C-terminal canine constant heavy or constant light chain sequences. Four distinct immunoglobulin gamma (IgG) heavy chain constant domain isotypes have been described in the canine immune system (Tang L. et al. 2001. Veterinary Immunology and Immunopathology, 80. 259-270) along with single kappa and lambda constant domain sequences.

The caninised  $\alpha$ D11 VH domain was combined with each of the four IgG heavy chain isotypes A, B, C and D and the caninised  $\alpha$ D11 VL domain with the canine kappa light chain constant domain. The sequences of the full-length mature antibody chains (caN) are shown in SEQ ID 5 (VL1 and canine kappa constant domain), 6 (VH1 and heavy chain isotype A), 7 (VH1 and heavy chain isotype B), 8 (VH1 and heavy chain isotype C) and 9 (VH1 and heavy chain isotype D). The sequence of a light chain of a variant antibody (caN2) is shown in SEQ ID No:10 (light chain variant (VL2) and canine kappa constant domain). The amino acid sequences for heavy chains of a variant antibody (caN2) are provided in SEQ ID NO:11 (HCA variant – VH2 and heavy chain isotype A), SEQ ID NO:12 (HCB variant – VH2 and heavy chain isotype B), SEQ ID NO:13 (HCC variant – VH2 and heavy chain isotype C) and SEQ ID NO:14 (HCD variant – VH2 and heavy chain isotype D).

The combined amino acid sequences were converted to expressible form in mammalian cells by the optimal selection of codons and full chemical gene synthesis and cloning into a mammalian cell expression vector pcDNA3.1+.

The resultant cDNAs were transfected into CHO cells and the supernatants from heavy chains having the sequences SEQ ID NO:6-9 were analysed in Example 2. Antibodies having the light chain sequence SEQ ID NO:10 and the heavy chain sequence SEQ ID NO:11 were purified in Example 11.

### Example 2 – Determining binding of antibodies to murine and canine NGF

Combinations of caninised heavy and light chain cDNAs were transfected into CHO cells, the supernatants harvested and reacted in ELISA format with either canine or murine NGF. Following incubation and wash steps, the bound canine antibody was detected by reactivity with a goat-anti canine IgG specific polyclonal antibody linked to horseradish peroxidase (HRP) and developed using TMB. The optical density of the resulting product was measured at 450nm and compared with that from mock empty vector transfected supernatant (denoted as “Mock” in Figure 1).

The results are shown in the graph of Figure 1. Binding to mouse NGF is shown for 4 caninised antibodies. Each of these antibodies has the same light chain (caN-kLC-1), that is a light chain comprising a canine kappa constant domain. Each antibody has a different heavy chain constant domain. Accordingly a specific heavy chain variable domain is combined with one of 4 different constant domains (caN-HCA, caN-HCB, caN-HCC or caN-HCD). In the second part of the graph, binding of a single antibody comprised of the caN-kLC-1 light chain and the caN-HCB constant chain to canine NGF is shown.

#### Example 3 – Purification of caninised antibodies

The supernatants obtained from Example 2 were purified using a Protein A column, separated by SDS-PAGE and tested for reactivity to the anti-canine IgG polyclonal antibody HRP. This polyclonal antibody preferentially recognises the heavy chains.

The results are shown in Figure 2 A-D. Legend: A - HCA is a caninised antibody comprising the caN-HCA heavy chain and caN-kLC light chain, HCB is a caninised antibody comprising the caN-HCB heavy chain and the caN-kLC light chain, C - HCC is a caninised antibody comprising the caN-HCC heavy chain and a caN-kLC light chain, D - HCD is a caninised antibody comprising the caN-HCA heavy chain and a caN-kLC light chain. With each of Figures 2A-D, L means load, W means wash, P means peak fraction, and F means flow through.

It can be seen that Protein A preferentially binds to the HCB isotype (i.e. a caninised antibody comprising the caN-HCB heavy chain), whereas significant material is not retained and is easily washed off of Protein A by the HCA, HCC and HCD isotypes.

5

#### Example 4 – Analysis of purified caninised antibodies using SDS-PAGE

Representative fractions of the peaks from the gels shown in Example 2 (Figures 2A-D) were separated by SDS-PAGE and stained with Coomassie blue.

10 The results are shown in the gel shown in Figure 3. This gel shows that heavy and light chains are clearly visible. Order of lanes from left: Lane 1 - Size standards, Lane 2 - HCA caN-HCA + caN-kLC1, Lane 3 - HCB caN-HCB + caN-kLC1, Lane 4 - HCC caN-HCC + caN-kLC1, Lane 5 - HCD caN-HCA + caN-kLC.

#### Example 5 - Inhibition of NGF induced proliferation of TF-1 cells by caninised antibodies

Serial dilutions of CHO cell transfectant supernatants from Example 2 ("antagonist") were incubated with TF-1 cells in the presence of 0.3 ng/mL NGF. The resultant proliferation was measured by thymidine incorporation.

20

The results are shown in Figure 4. 50% inhibition was observed at a calculated 0.75- 1.5 ng/mL monoclonal antibody (MAb).

#### Example 6 - Complement deposition induced by antigen-captured caninised antibodies

25

CHO cell transfectant supernatants from Example 2 were incubated with plates coated with 0.1 ng/mL NGF to capture the antibodies. The plates were washed and then incubated with human serum and bound complement C1q was measured by binding of anti-human C1q polyclonal antibody HRP and developed as above.

30

Complement Binding Method

Plates were coated with 100 µl/well of 5 µg/ml mouse NGF and blocked with 5% BSA/PBS. Coated wells were incubated for 1 hour at room temperature with cell culture supernatants, containing recombinant caninised anti-NGF IgG, diluted in PBS/1% BSA (100 µl/well). The plates were washed and incubated for 1 hour at room temperature with 100 µl/well of human serum diluted 1/100 in veronal buffered saline containing 0.5 mM MgCl<sub>2</sub>, 2 mM CaCl<sub>2</sub>, 0.05% Tween-20, 0.1% gelatin and 0.5% BSA. After washing, plates were incubated with 100 µl of a 1/800 dilution of sheep anti-C1q-HRP (Serotec) in PBS/1% BSA. After washing, plates were developed by the addition of 100µl TMB substrate (Thermo Scientific). Development was stopped by the addition of 100 µl of 2N H<sub>2</sub>SO<sub>4</sub> and absorbance read at 450 nm.

The results are shown in the graph of Figure 5. These results show binding of C1q to immobilised caninised HCB and HCC type antibodies and no binding of C1q to caninised HCA and HCD type antibodies. Hence, the results surprisingly indicate that different canine derived heavy chains exhibit different complement binding and activation characteristics and that the caninised antibodies with type HCA and HCD heavy chains have been unexpectedly shown to be preferable for use in antagonising canine NGF. The identification of canine derived heavy chains which do not mediate complement fixing is a particularly advantageous finding as NGF is a soluble mediator.

#### Example 7 – Comparison of the binding of anti-canine-NGF monoclonal antibodies to NGF

A comparison of the binding of anti-canine-NGF monoclonal antibodies to NGF using frameworks VL1 and VH1 (SEQ ID NO:1 and 2) versus alternate frameworks VL2 and VH2 (SEQ ID NO:3 and 4) was carried out. DNA encoding the light and heavy chains described by SEQ ID NO:10 and SEQ ID NO:11 were synthesised and cloned into pcDNA3.1+ downstream of secretory signal sequence peptides. The DNAs were co-transfected into CHO cells and the supernatant compared by binding ELISA to mouse NGF with CHO supernatant from co-expression of SEQ ID NO:5 plus SEQ ID NO:7.

The results are shown in Figure 13A. Lanes A-D show supernatant (undiluted, 1/10, 1/100, 1/1000 respectively) from SEQ ID NO:5 and SEQ ID NO:7. Lanes E-H show supernatant (undiluted, 1/10, 1/100, 1/1000 respectively) from SEQ ID NO:10 and SEQ ID NO:11. Lane I shows an undiluted negative control supernatant.

Example 8 - Complement deposition induced by NGF-captured caninised antibodies

CHO cell transfectant supernatants from Example 7 were tested for their ability to recruit complement using a C1q ELISA assay (using the method described in Figure 5).

The results are shown in Figure 13B. The combination of VL2 (in SEQ ID 10) and VH2 frameworks plus HCA type constant domains (SEQ ID 11) was inactive at recruiting complement despite equivalent binding to NGF observed in Panel A to that of the HCB type heavy chain in MAb (SEQ ID 5+7). The MAbs were tested in a dilution series of 4, 2 and 1 ug/ml. C was a negative control.

Example 9 - Comparison of binding to NGF of N-glycosylated and aglycosylated variants of anti-canine-NGF monoclonal antibodies with HCB and HCC heavy chain isotypes

A comparison of the binding of N-glycosylated and aglycosylated variants of anti-canine-NGF monoclonal antibodies to NGF with HCB and HCC heavy chain isotypes was carried out. Expression vectors encoding the light and heavy chain pairs described by SEQ ID NO:5 and SEQ ID NO:7 (HCB), SEQ ID NO:5 and SEQ ID NO:16 (HCB\*), SEQ ID NO:5 and SEQ ID NO:8 (HCC), or SEQ ID NO:5 and SEQ ID NO:17 (HCC\*) were co-transfected into CHO cells and the supernatants compared by binding ELISA to mouse NGF.

The results are shown in Figure 14A. The white boxes show undiluted supernatant, the shaded boxes show a 1/100 dilution and C shows an undiluted

negative control supernatant. Equivalent binding to NGF was observed.

Example 10 - Complement deposition induced by NGF-captured caninised antibodies

5 CHO cell transfectant supernatants from Example 9 were tested for their ability to recruit complement using a C1q ELISA assay (using the method described in Figure 5).

10 The results are shown in Figure 14B. The ability to recruit complement C1q was abolished by removal of the N-linked glycosylation site in the B type heavy chain (HCB\*) and was diminished by a similar mutation in the C type heavy chain (HCC\*).

15 Accordingly, it is demonstrated herein, quite surprisingly, that where an antibody of the invention has a canine derived heavy chain of the HCA or HCD subtype, the binding of the antibody to canine NGF does not result in complement activation or other downstream effector functions, such as ADCC. Hence, said antibodies, in antagonising the biological functional activity of canine NGF by preventing binding of canine NGF to the membrane bound TrkA or p75 receptors, inhibit the  
20 associated downstream intracellular signalling cascade. Furthermore, as NGF expression frequently occurs in the proximity of nerves and the like, the NGF antagonising or neutralising antibodies of the invention, which have canine derived heavy chain of the HCA or HCD subtype, can sequester canine NGF biological activity without recruiting a wider immune response. Such functional properties  
25 are unexpected, yet highly desirable.

Example 11: Purification of anti-NGF monoclonal antibodies following expression in CHO cells

30 Since canine anti-NGF monoclonal antibodies of the HCA and HCD isotypes have desirable lack of binding to complement (Figure 5), but bind weakly to Staphylococcus Protein A (Figure 2), alternative methods of purification were developed. Anti-canine NGF monoclonal antibodies derived from expression

vectors expressing SEQ ID NO:10 (light chain variant (VL2) and canine kappa constant domain) and SEQ ID NO:11 (HCA variant – VH2 and heavy chain isotype A) were expressed in CHO cells and following extensive experimentation it was found that the canine anti-NGF antibody could be fractionated to high purity by two alternative purification methods.

In the first method, anti-canine NGF monoclonal antibody was purified by anion exchange chromatography, hydrophobic interaction chromatography and size exclusion chromatography (Method I - Figure 15A and B). In the second method, the anti-NGF antibody could be purified by Captopadhere affinity chromatography followed by anion exchange chromatography (Method II - Figure 15C and D).

The main peak of anti-NGF monoclonal antibody purified by either method corresponds to a molecular weight of approximately 150 kDa. Comparison by SDS-PAGE and ELISA (Figure 16) illustrates that Methods I and II produce antibody preparations with similar purity and bioactivity. Purified anti-NGF monoclonal antibodies produced by these methods were tested in the TF-1 NGF neutralisation assay (described in Figure 4) and shown to have high potency (IC<sub>50</sub> 13 pM anti-NGF neutralised 37 pM NGF; not shown).

Example 12: Anti-canine NGF monoclonal antibodies can be safely administered intravenously to canines and do not cause pyrexia

Anti-canine NGF monoclonal antibodies derived from expression vectors expressing SEQ ID NO:10 and SEQ ID NO:11 (canine HCA type heavy chain) were expressed in CHO cells and purified by a combination of ion exchange chromatography, hydrophobic interaction chromatography and size exclusion chromatography (Method I, Figure 15A and B) and buffer exchanged into phosphate buffered saline. The antibodies were injected intravenously into beagle dogs at 2 mg/kg body weight and assessed for signs of toxicity by visual inspection by a veterinarian, change in body weight, body temperature and plasma biochemistry. Figure 17 illustrates the body weight and temperature measurements. No changes were observed in these or any plasma biochemistry



analyte measured (including sodium, potassium, chloride, calcium, phosphate, urea, creatinine, glucose, cholesterol, bilirubin, alanine transaminase, alkaline phosphatase, amylase, lipase, total protein or albumin: not shown).

5 Example 13. Plasma pharmacokinetics of anti-canine NGF monoclonal antibodies in vivo demonstrates long serum half-life and lack of immunogenicity

Anti-canine NGF monoclonal antibodies derived from expression vectors expressing SEQ ID NO:10 and SEQ ID NO:11 (canine HCA type heavy chain) were expressed in CHO cells and purified by a combination of ion exchange  
10 chromatography, hydrophobic interaction chromatography and size exclusion chromatography and buffer exchanged into phosphate buffered saline (Method 1, Figure 15A and B). The antibodies were injected intravenously into beagle dogs at 2 mg/kg body weight and plasma samples were taken at various times over the following 2 weeks. Diluted plasma samples were assessed for anti-canine NGF  
15 antibody concentration by ELISA using NGF as target and anti-canine polyclonal antibody-horseradish peroxidase secondary reagent and developed as per Figure 1. The results are shown in Figure 18. The plasma concentrations measured were consistent with two-phase kinetics, with a tissue distribution (alpha) phase half-life of approximately 33 hours and surprisingly long elimination (beta) phase of  
20 approximately 9 days.

The absence of a sharp decline in plasma concentration of anti-canine NGF antibody concentration between 100 and 300 hours demonstrates that there are neither pre-existing neutralising antibodies to recombinant anti-NGF monoclonal  
25 antibodies in dog blood nor were any such neutralising antibodies generated following infusion. By comparison, recombinant human immunoglobulin based proteins are neutralised by antibodies in dog blood at approximately 200 hours post infusion (Richter et al, Drug Metabolism and Disposition 27: 21, 1998). These results therefore show that anti-canine NGF antibodies of the present invention  
30 have a long serum half life (9 days) in vivo following intravenous injection and that there are neither pre-existing antibodies nor newly generated antibodies that neutralise the injected anti-NGF antibodies over time.

Example 14 – Effect of anti-canine NGF monoclonal antibodies in reducing inflammatory pain in vivo

*Antibody therapy:*

5 Anti-canine NGF monoclonal antibodies derived from expression vectors expressing SEQ ID NO:10 and SEQ ID NO:11 (canine HCA type heavy chain) were expressed in CHO cells and purified by a combination of ion exchange chromatography, hydrophobic interaction chromatography and size exclusion chromatography (Method I) and buffer exchanged into phosphate buffered saline.

10

*Canine model of inflammation:*

All experiments were carried out with prior approval of the Institutional Ethics Committee (CRL, Ireland). Beagle dogs were injected (= day -1) with kaolin into the footpad of one hind leg in order to generate a self-resolving inflammation beginning approximately 24 hours later and which causes the dogs to become temporarily lame. In this model, once the initial inflammation response to kaolin recedes, the dogs become steadily less lame over the period of approximately 1-2 weeks and then make a full recovery.

15

20 Groups of 3 dogs were injected intravenously with either anti-canine NGF monoclonal antibodies at 200 µg/kg body weight or phosphate buffered saline as vehicle control (= day 0). The dogs were assessed for lameness over 7 days by a visual scoring method (score 0, no lameness (full weight bearing); score 1, slight lameness (not full weight bearing but walking well); score 2, moderate lameness (slightly weight bearing and not walking well), score 3, severe lameness (not weight bearing)). Observers were blinded to which dogs received which injection.

25

The results are shown in Figure 19. Lameness scores were reduced in the dogs receiving anti-NGF monoclonal antibodies by day 3 post-injection compared with vehicle control, indicating that the anti-NGF monoclonal antibodies had an effect in reducing the pain in the dogs over that seen with vehicle alone. The delayed activity is consistent with the plasma pharmacokinetics of anti-canine NGF

30

monoclonal antibodies which demonstrated a slow tissue distribution (alpha) phase of approximately 30 hours and the relatively poor vascularisation of the footpad area. The results shown in Figure 19 show that the anti-canine NGF antibodies of the present invention reduce inflammatory pain in dogs with a consequent reduction in lameness.

The scope of the claims should not be limited by the preferred embodiment and examples, but should be given the broadest interpretation consistent with the description as a whole. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes of carrying out the invention which are obvious to those skilled in the art are intended to be covered by the present invention.

**CLAIMS**

1. A caninized antibody comprising a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:3, wherein the light chain variable region comprises a CDR1 sequence comprising RASEDIYNALA (residues 24-34 of SEQ ID NO:1 or SEQ ID NO:3), a CDR2 sequence comprising NTDTLHT (residues 50-56 of SEQ ID NO:1 or SEQ ID NO:3), and a CDR3 sequence comprising QHYFHYPRT (residues 89-97 of SEQ ID NO:1 or SEQ ID NO:3), and a heavy chain variable region comprising an amino acid sequence selected from group consisting of SEQ ID NO:2 and SEQ ID NO:4, wherein the heavy chain variable region comprises a CDR1 sequence comprising NNNVN (residues 31-35 of SEQ ID NO:2 or SEQ ID NO:4), a CDR2 sequence comprising GVVAGGATDYN SALKS (residues 50-65 of SEQ ID NO:2 or SEQ ID NO:4), and a CDR3 sequence comprising DGGYSSSTLYAMDA (residues 98-111 of SEQ ID NO:2 or SEQ ID NO:4), and wherein the antibody specifically binds to canine nerve growth factor (NGF) and inhibits the ability of canine NGF to bind to the p75 or the TrkA canine NGF receptor.
2. The antibody as claimed in claim 1, wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:1 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2.
3. The antibody as claimed in claim 1, wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:3 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4.
4. The antibody as claimed in claim 1, wherein the light chain comprises the amino acid sequence of SEQ ID NO:5.
5. The antibody as claimed in claim 1, wherein the light chain comprises the amino acid sequence of SEQ ID NO:10.

6. The antibody as claimed in claim 1, wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9.
7. The antibody as claimed in claim 1, wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14.
8. The antibody as claimed in claim 1, wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:18.
9. The antibody as claimed in claim 1, wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21 and SEQ ID NO:22.
10. The antibody as claimed in claim 1, wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:15 and SEQ ID NO:18.
11. The antibody as claimed in claim 1, wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:19, and SEQ ID NO:22.
12. An antibody comprising a light chain variable region comprising SEQ ID NO:1 and a heavy chain variable region comprising SEQ ID NO:2, wherein the light chain variable region comprises:
  - a CDR1 sequence comprising RASEDIYNALA (residues 24-34 of SEQ ID NO:1), a CDR2 sequence comprising NTDTLHT (residues 50-56 of SEQ ID NO:1), and a CDR3 sequence comprising QHYFHYPRT (residues 89-97 of SEQ ID NO:1);
  - an FR1 framework region comprising or consisting of the amino acid sequence of SEQ ID NO:23,

an FR2 framework region comprising or consisting of the amino acid sequence of SEQ ID NO:25,

an FR3 framework region comprising or consisting of the amino acid sequence of SEQ ID NO:27, and

an FR4 framework region comprising or consisting of the amino acid sequence of SEQ ID NO:28,

and wherein the heavy chain variable region comprises:

a CDR1 sequence comprising NNNVN (residues 31-35 of SEQ ID NO:2), a CDR2 sequence comprising GVVAGGATDYN SALKS (residues 50-65 of SEQ ID NO:2), and a CDR3 sequence comprising DGGYSSSTLYAMDA (residues 98-111 of SEQ ID NO:2);

an FR1 framework region comprising or consisting of the amino acid sequence of SEQ ID NO:29,

an FR2 framework region comprising or consisting of the amino acid sequence of SEQ ID NO:30,

an FR3 framework region comprising or consisting of the amino acid sequence of SEQ ID NO:32, and

an FR4 framework region comprising or consisting of the amino acid sequence of SEQ ID NO:33,

and wherein the antibody specifically binds to canine nerve growth factor (NGF) and inhibits the ability of canine NGF to bind to the p75 or the TrkA canine NGF receptor.

13. An antibody comprising a light chain variable region comprising SEQ ID NO:1 and a heavy chain variable region comprising SEQ ID NO:2, wherein the light chain variable region comprises:

an FR1 framework region comprising or consisting of the amino acid sequence of SEQ ID NO:23,

an FR2 framework region comprising or consisting of the amino acid sequence of SEQ ID NO:25,

an FR3 framework region comprising or consisting of the amino acid sequence of SEQ ID NO:27, and

an FR4 framework region comprising or consisting of the amino acid sequence of SEQ ID NO:28,

and wherein the heavy chain variable region comprises:

an FR1 framework region comprising or consisting of the amino acid sequence of SEQ ID NO:29,

an FR2 framework region comprising or consisting of the amino acid sequence of SEQ ID NO:30,

an FR3 framework region comprising or consisting of the amino acid sequence of SEQ ID NO:32, and

an FR4 framework region comprising or consisting of the amino acid sequence of SEQ ID NO:33.

14. The antibody as claimed in any one of claims 1, 2, 12 and 13 comprising a heavy chain constant domain that does not mediate downstream effector functions, wherein the heavy chain constant domain is an aglycosylated type HCB canine heavy chain constant domain (residues 123-457 of SEQ ID NO:16), an aglycosylated type HCA canine heavy chain constant domain (residues 123-453 of SEQ ID NO:15) or an aglycosylated type HCD canine heavy chain constant domain (residues 123-453 of SEQ ID NO:18) or a type HCA canine heavy chain constant domain (residues 123-453 of SEQ ID NO:6) or HCD (residues 123-453 of SEQ ID NO:9) canine heavy chain constant domain.

15. A pharmaceutical composition comprising the antibody as claimed in any one of claims 1 to 14, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

16. The antibody as claimed in any one of claims 1 to 14 for use in the treatment of pain in a canine, or for use in the treatment, amelioration or inhibition of pain associated with immune mediated polyarthritis, osteoarthritis or rheumatoid arthritis in a canine.

17. A kit for the treatment of pain in a canine, or for the treatment, amelioration or inhibition of pain associated with osteoarthritis, immune

mediated polyarthritis or rheumatoid arthritis in a canine, comprising the antibody according to any one of claims 1 to 14 together with at least one pharmaceutically acceptable carrier, excipient or diluent and instructions for use of the same.



1/23




Figure 1

2/23




Figure 2

3/23




Figure 3

4/23




Figure 4

5/23




Figure 5

```

* * * * *
Caninised VL 40 DIQMTQSPASLSLSQEEKVTITCRASEDIYNALAWYQQKP
* * * * *
Caninised VL 80 GQAPKLLIYNTDTLHTGVPSRFGSGSGTEYSLTINSLES
* * * * *
Caninised VL 107 EDVAVYFCQHYFHYPRTFGAGTKVELK

```

7/23

		*	*	**	*	**	*	*	*
Caninised VH		E	V	Q	L	V	E	S	G
40		G	D	L	V	N	P	G	G
		T	L	S	C	V	V	S	G
		F	S	L	<u>T</u>	<u>N</u>	<u>N</u>	<u>N</u>	<u>V</u>
		<u>W</u>	<u>R</u>	<u>Q</u>	<u>A</u>				
		*		*					*
Caninised VH		L	G	R	G	L	E	W	V
80		G	G	V	W	A	G	G	A
		T	D	Y	N	S	A	L	K
		S	R	L	T	I	T	R	D
		T	S	K	S	T	V	F	L
		82ABC				100ABCDEF			*
Caninised VH		K	M	H	S	L	Q	S	E
113		D	T	A	T	Y	C	A	R
		D	G	G	Y	S	S	T	L
		<u>Y</u>	<u>A</u>	<u>M</u>	<u>D</u>	<u>A</u>	<u>W</u>	<u>G</u>	<u>Q</u>
		<u>G</u>	<u>T</u>	<u>L</u>	<u>V</u>	<u>T</u>	<u>V</u>	<u>S</u>	<u>S</u>

Figure 7 – Heavy chain variable domain

8/23

DIQMTQSPASLSLSQEEKVTITCRASEDIYNALAWYQ  
QKPGQAPKLLIYNTDTLHTGVPSRFSGSGSGTEYSLTI  
NSLESEDVAVYFCQHYPRTFGAGTKVELKRND  
QPAVYLFQSPDQLHTGSASVVCLLSFYPKDINVKW  
KVDGVIQDTGIQESVTEQDKDSTYSLSSTLTMSSTEYL  
SHELYSCEITHKSLPSTLIKSFRSECQRVD

Figure 8 – Caninised anti-NGF VL canine kappa light chain (caN-kLC)



9/23

EVQLVESGGDLVNPGGTLTSCVVSGFSLTNNNVNWVR  
QALGRGLEWVGGVWAGGATDYN SALKSRLTITRDT SKS  
TVFLKMHSLQSEDTATYYCARDGGYSSSTLYAMDAWG  
QGTLVTVSSASTTAPSVFPLAPSCGSTSGSTVALACLVS  
GYFPEPVTVSWNSGSLTSGVHTFPSVLQSSGLHSLSSMV  
TVPSSRWPSETFTCNVHPASNTKVDKPVFNECRCTDTP  
PCPVPEPLGGPSVLIFPPKPKDILRITRTPEVTCVLDLGR  
EDPEVQISWFVDGKEVHTAKTQSREQQFNGTYRVVSVL  
PIEHQDWLTGKEFKCRVNHIDLPSP IERTISKARGRAHKP  
SVYVLPPSPKELSSSDTVSITCLIKDFYPPDIDVEWQSNG  
QQEPERKHRMTPPQLDEDGSYFLYSKLSVDKSRWQQG  
DPFTCAVMHETLQNH YTDLSLSHSPGK

Figure 9 – Caninised anti-NGF VH canine IgG-A heavy chain  
(caN-HCA)

10/23

EVQLVESGGDLVNPGGTLTLSCVVS GFSLTNNNVNWVR  
QALGRGLEWVGGVWAGGATDYN SALKSRLTITRDTSKS  
TVFLKMHSLQSEDTATYYCARDGGYSSSTLYAMD AWG  
QGTLVTVSSASTTAPSVFPLAPSCGSTSGSTVALACLVS  
GYFPEPVTVSWNSGSLTSGVHTFPSVLQSSGLYSLSSMV  
TVPSSRWPSETFTCNVAHPASKTKVDKPVPKRENGRVP  
RPPDCPKCPAPEMLGGPSVFIFPPKPKDTLLIARTPEVTC  
VVVDLDPEDPEVQISWFVDGKQMQTAKTQPREEQFN GT  
YRVVSVLPIGHQDWLKGKQFTCKVNNKALPSPIERTIS KA  
RGQAHQPSVYVLPPSREELSKNTVSLTCLIKDFYPPDIDV  
EWQSNGQQEPESKYRTTPQLDEDGSYFLYSKLSVDKS  
RWQRGDTFICAVMHEALHNHYTQESLSHSPGK

Figure 10 – Caninised anti-NGF VH canine IgG-B heavy chain (caN-HCB)

11/23

EVQLVESGGDLVNPGGTLTLSCVVSGFSLTNNNVNWVR  
QALGRGLEWVGGVWAGGATDYN SALKSRLTITRDTSKS  
TVFLKMHS LQSEDTATYYCARDGGYSSSTLYAMD AWG  
QGTLVTVSSASTTAPSVFPLAPSCGSQSGSTVALACLVS  
GYIPEPVTVSWNSVSLTSGVHTFPSVLQSSGLYSLSSMV  
TVPSSRWPSETFTCNVAHPATNTKVDKPVAKECECKCN  
CNNCPCPGCGLLGGPSVFIFPPKPKDILVTARTPTVTCVV  
VDLDPENPEVQISWFVDSKQVQTANTQPREEQSNGTYR  
VVSVLPIGHQDWLSGKQFKCKVNNKALPSPIEEIISKTPG  
QAHQPNVYVLPSPRDEM SKNTVTLTCLVKDFFPPEIDVE  
WQSN GQQEPESKYRMT PPQLDEDGSYFLYSKLSVDKSR  
WQRGDTFICAVMHEALHNHYTQISLSHSPGK

Figure 11 – Caninised anti-NGF VH canine IgG-C heavy chain (caN-HCC)

12/23

EVQLVESGGDLVNPGGTTLTSCVVSGFSLTNNNVNWVR  
QALGRGLEWVGGVWAGGATDYN SALKSRLTITRDT SKS  
TVFLKMHSLQSEDTATYYCARDGGYSSSTLYAMD AWG  
QGTLVTVSSASTTAPSVFPLAPSCGSTSGSTVALACLVS  
GYFPEPVTVSWNSGSLTSGVHTFPSVLQSSGLYSLSTV  
TVPSSRWPSETFTCNV VHPASNTKVDKVPKESTCKCIS  
PCVPESLGGPSVFIFPPKPKDILRITRTPEITCVVLDL GRE  
DPEVQISWFVDGKEVHTAKTQPREQQFNSTYRVVSVLPI  
EHQDWLTGKEFKCRVNHIGLPSPIERTISKARGQAHQPS  
VYVLPPSPKELSSSDTVTLTCLIKDFYPPEIDVEWQSN GQ  
PEPESKYHTTAPQLDEDGSYFLYSKLSVDKSRWQQGDT  
FTCAVMHEALQNHYTDLSLSHSPGK

Figure 12 – Caninised anti-NGF VH canine IgG-D heavy chain (caN-HCD)

13/23




Figure 13A




Figure 13B

14/23




Figure 14A




Figure 14B

15/23




Figure 15A

16/23




Figure 15B



17/23



**SDS-PAGE**

Figure 15C

18/23



Peak Retention time (Mins)	Approximate MW (KDa)	% of Total Peak area
8.05	353	2.6
9.17	156	89.7
11.18	36	7.7

Figure 15D


19/23  
SDS-PAGE

Figure 16A

20/23

## NGF ELISA




Figure 16B

21/23

Study Day			-1	1	3	7
Animal ID	Sex	Age on Study Day 0 (months)				
68305	M	11	9.6	10.0	9.9	10.0
26885	F	19	9.2	9.9	9.5	9.8
32886	F	11	9.4	9.9	9.7	10.0

Study Day	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Animal ID															
68305	38.2	38.6	38.6	38.5	38.4	38.5	38.4	38.3	38.7	38.2	38.3	38.9	38.4	38.6	38.5
26886	37.8	38.2	38.0	38.2	38.4	37.7	38.1	38.2	38.4	38.2	38.4	38.6	38.5	38.4	38.6
32886	36.8	38.7	38.9	38.8	38.7	38.8	38.7	38.5	38.8	38.7	38.3	39.2	38.7	38.7	38.8

Figure 17

22/23




Figure 18

23/23




Figure 19

